CLDF Title
Home | Contact Us | Bookmark
 
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Webcasts Slide Library Abstract Library Conference Highlights
 
HBV-Single Disease Content  
Webcasts
     
  Xpert Gear  
     
  View Webcast  
     
  Purdue  
  Jointly sponsored by Purdue University College of Pharmacy and the Chronic Liver Disease Foundation.  
 
 
Goal Statement
The goal of this program is to provide important clinical data on the management of HBV.
 
Target Audience
This activity has been designed to meet the educational needs of healthcare practitioners involved in the care of patients with HBV
 
 
 
Slide Library
HBV 2011 Slides
Current Perspectives in the Management of Hepatitis B
 
HBV Slide Archive
HBV 2010 Slides
Managing Hepatitis B At Risk Community Hepatitis B
Hepatology 2010 Slides
Current Perspectives on Chronic Liver Disease
 
 
Abstract Library
  1. Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: A systematic review of randomized trials.
    Sun P, Yang X, He RQ, Hu QG, Song ZF, Xiong J, Zheng QC. Hepatol Res. 2013 Apr 2. doi: 10.1111/hepr.12115. [Epub ahead of print]


  2. Advance in molecular diagnostic tools for hepatitis B virus detection
    Pazienza V, Niro GA, Fontana R, Vinciguerra M, Andriulli A. Clin Chem Lab Med. 2013 Apr 6:1-11. doi: 10.1515/cclm-2013-0136. [Epub ahead of print]


  3. Liver Imaging with a Novel Hepatitis B Surface Protein Derived SPECT-Tracer
    Müller T, Mehrle S, Schieck A, Haberkorn U, Urban S, Mier W. Mol Pharm. 2013 May 3. [Epub ahead of print]


  4. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma
    Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Liver Int. 2013 Apr 2. doi: 10.1111/liv.12168. [Epub ahead of print]


  5. Optimal Testing of the Live Organ Donor for Blood-Borne Viral Pathogens: The Report of a Consensus Conference
    Blumberg EA, Ison MG, Pruett TL, Segev DL; on behalf of the Optimal Testing of the Live Organ Donor Consensus Conference Participants. Am J Transplant. 2013 Apr 19. doi: 10.1111/ajt.12205. [Epub ahead of print]


  6. Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B
    Li X, Wang Y, Han D, Zhang W, Zhang Z, Ye X, Tian L, Dong Y, Zhu Q, Chen Y. Hepatol Res. 2013 Mar 4. doi: 10.1111/hepr.12105. [Epub ahead of print]


  7. Molecular virology of chronic hepatitis B and C: Parallels, contrasts and impact on drug development and treatment outcome
    Delaney WE 4th. Antiviral Res. 2013 Apr 18. pii: S0166-3542(13)00096-X. doi: 10.1016/j.antiviral.2013.04.010. [Epub ahead of print]


  8. Association of the rs3077 and rs9277535 polymorphisms in HLA-DP with hepatitis B virus infection and spontaneous clearance: A meta-analysis
    Zhang XL, Ni XC, Jia JH, Dong JH, Yu FX, Ma N, Liu XH, Li M, Liu DW. Scand J Gastroenterol. 2013 Apr 22. [Epub ahead of print]


  9. Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B
    Tanaka E, Matsumoto A. Hepatol Res. 2013 Mar 8. doi: 10.1111/hepr.12108. [Epub ahead of print]


  10. Diagnostic accuracy of hepatic venous pressure gradient measurement in the prediction of stage 1 compensated liver cirrhosis in patients with chronic hepatitis B
    Suk KT, Kim HC, Namkung S, Han SH, Choi KC, Park SH, Sung HT, Kim CH, Kim SH, Ham YL, Kang HM, Kim DJ. Eur J Gastroenterol Hepatol. 2013 Apr 18. [Epub ahead of print]


  11. Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice
    Salpini R, Alteri C, Cento V, Pollicita M, Micheli V, Gubertini G, De Sanctis GM, Visca M, Romano S, Sarrecchia C, Andreoni M, Angelico M, Parruti G, Svicher V, Perno CF. J Med Virol. 2013 Jun;85(6):996-1004. doi: 10.1002/jmv.23567.


  12. Reactivation of hepatitis B virus associated with chemotherapy and immunosuppressive agent
    Wijaya I, Hasan I. Acta Med Indones. 2013 Jan;45(1):61-6.


  13. Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B
    Hagiwara S, Kudo M, Osaki Y, Matsuo H, Inuzuka T, Matsumoto A, Tanaka E, Sakurai T, Ueshima K, Inoue T, Yada N, Nishida N. J Med Virol. 2013 Jun;85(6):987-95. doi: 10.1002/jmv.23564.


  14. Association between gene polymorphisms of IL-28 and response to lamivudine in Chinese rural patients with chronic hepatitis B
    Yu F, Wang Y, Yuan S, Ma J, Ma N, Zhang X, Liu X, Liu D. Scand J Gastroenterol. 2013 Apr 16. [Epub ahead of print]


  15. Does Guasha Offer Hepatoprotective Effect to Chronic Inactive Hepatitis B Carriers? A Built-in Design to Control Subject Expectation
    Chan ST, Yuen JW, Gohel MD, Wong HC, Chung CP, Sun Y, Ng JN, Lie R, Kwong KK. J Altern Complement Med. 2013 Apr 11. [Epub ahead of print]


  16. Hepatitis B and C infection in international travelers
    Johnson DF, Leder K, Torresi J. J Travel Med. 2013 May;20(3):194-202. doi: 10.1111/jtm.12026. Epub 2013 Apr 4.


  17. Peginterferon-2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study
    Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.


  18. Long-term therapy for chronic hepatitis B: HBV DNA suppression leading to cirrhosis reversal
    Marcellin P, Asselah T. J Gastroenterol Hepatol. 2013 Apr 11. doi: 10.1111/jgh.12213. [Epub ahead of print]


  19. Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study
    Marcellin P, Arama V, Leblebicioglu H, Zarski JP, Zeuzem S, Mauss S, Sieklucki J, Acalovschi M, Usluer G, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Simon K; the AI; Longitudinal Study Group. Antivir Ther. 2013 Apr 10. doi: 10.3851/IMP2573. [Epub ahead of print]


  20. Coinfection with Hepatitis B and D: Epidemiology, Prevalence and Disease in Patients in Northern California
    Gish RG, Yi DH, Kane S, Clark M, Mangahas M, Baqai S, Winters MA, Proudfoot J, Glenn JS. J Gastroenterol Hepatol. 2013 Apr 11. doi: 10.1111/jgh.12217. [Epub ahead of print]


  21. Update in the management of chronic hepatitis B
    Tujios SR, Lee WM. Curr Opin Gastroenterol. 2013 May;29(3):250-6. doi: 10.1097/MOG.0b013e32835ff1e9.


  22. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B
    Tanaka M, Suzuki F, Seko Y, Hara T, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. J Gastroenterol. 2013 Mar 26. [Epub ahead of print]


  23. Liver transplantation in hepatitis B core negative recipients using livers from hepatitis B core positive donor: 13 years experience
    Bohorquez HE, Cohen AJ, Girgrah N, Bruce DS, Carmody IC, Joshi S, Reichman TW, Therapondos G, Mason AL, Loss GE. Liver Transpl. 2013 Mar 22. doi: 10.1002/lt.23644. [Epub ahead of print]


  24. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease
    Chen FW, Coyle L, Jones BE, Pattullo V. Liver Int. 2013 Mar 2. doi: 10.1111/liv.12154. [Epub ahead of print]


  25. Significance of anti-HBc only in blood donors: a serological and virological study after hepatitis B vaccination
    Gessoni G, Beggio S, Barin P, Favarato M, Galli C, Valverde S, Nata MB, Salvadego MM, Marchiori G. Blood Transfus. 2013 Feb 21:1-6. doi: 10.2450/2013.0227-12. [Epub ahead of print]


  26. Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response
    Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M. Liver Int. 2013 Mar 7. doi: 10.1111/liv.12150. [Epub ahead of print]


  27. Prediction models of long-term cirrhosis and HCC risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles
    Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, You SL, Wang LY, Chen CJ; for the R.E.V.E.A.L.-HBV Study Group. Hepatology. 2013 Mar 15. doi: 10.1002/hep.26385. [Epub ahead of print]


  28. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
    Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, Rothe V, Popescu M, Brunetto MR. Hepatol Int. 2013 Mar;7(1):88-97. Epub 2012 Mar 23.


  29. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
    Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, Rothe V, Popescu M, Brunetto MR. Hepatol Int. 2013 Mar;7(1):88-97. Epub 2012 Mar 23.


  30. Occult hepatitis B virus infection as a cause of posttransfusion hepatitis in patients with cancers
    Sodhi JS, Wani N, Jeelani S, Geelani S, Akhtar F, Javid G, Yattoo GN, Shah A, Gulzar GM, Khan MA, Parveen S, Saif RU, Showkat A. Indian J Gastroenterol. 2013 Mar 20. [Epub ahead of print]


  31. Association Between Metabolic Syndrome and Its Individual Components With Viral Hepatitis B
    Jinjuvadia R, Liangpunsakul S. Am J Med Sci. 2013 Mar 19. [Epub ahead of print]


  32. Role of maternal viremia and placental infection in hepatitis B virus intrauterine transmission
    Chen Y, Wang L, Xu Y, Liu X, Li S, Qian Q, Hu B, Zhou A, Chen T, Zhao Y. Microbes Infect. 2013 Mar 14. pii: S1286-4579(13)00037-3. doi: 10.1016/j.micinf.2013.02.008. [Epub ahead of print]


  33. Immunoglobulin g4-associated de novo autoimmune hepatitis after liver transplantation for chronic hepatitis B- and C-related cirrhosis and hepatocellular carcinoma: a case report with literature review
    Zhao XY, Rakhda MI, Wang TI, Jia JD. Transplant Proc. 2013 Mar;45(2):824-7. doi: 10.1016/j.transproceed.2012.02.049.


  34. APRI, the FIB-4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B
    Ucar F, Sezer S, Ginis Z, Ozturk G, Albayrak A, Basar O, Ekiz F, Coban S, Yuksel O, Armutcu F, Akbal E. Eur J Gastroenterol Hepatol. 2013 Mar 18. [Epub ahead of print]


  35. The diagnostic value of non-invasive tests for the evaluation of liver fibrosis in chronic hepatitis B patients
    Erdogan S, Dogan HO, Sezer S, Uysal S, Ozhamam E, Kayacetin S, Koca Y. Scand J Clin Lab Invest. 2013 Mar 20. [Epub ahead of print]


  36. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naive patients treated with entecavir
    Gish RG, Chang TT, Lai CL, de Man RA, Gadano A, Llamoso C, Tang H. Antivir Ther. 2013 Mar 19. doi: 10.3851/IMP2559. [Epub ahead of print]


  37. Connective tissue growth factor (CTGF/CCN2) in serum is an indicator of fibrogenic progression and malignant transformation in patients with chronic hepatitis B infection
    Gressner OA, Fang M, Li H, Lu LG, Gressner AM, Gao CF. Clin Chim Acta. 2013 Mar 15;421C:126-131. doi: 10.1016/j.cca.2013.02.029. [Epub ahead of print]


  38. Assessing Adherence to Accepted National Guidelines for Immigrant and Refugee Screening and Vaccines in an Urban Primary Care Practice: A Retrospective Chart Review
    Waldorf B, Gill C, Crosby SS. J Immigr Minor Health. 2013 Mar 20. [Epub ahead of print]


  39. Adefovir treatment for chronic hepatitis B in heart transplant recipients
    Durante-Mangoni E, Iossa D, Pinto D, Molaro R, Agrusta F, Amarelli C, Ragone E, Grimaldi M, Maiello C, Utili R. Clin Transplant. 2013 Mar 21. doi: 10.1111/ctr.12109. [Epub ahead of print]


  40. Telbivudine treatment in chronic hepatitis B: experience from China
    You H, Jia J. J Viral Hepat. 2013 Apr;20 Suppl 1:3-8. doi: 10.1111/jvh.12058.


  41. Efficacy of postoperative antiviral combined transcatheter arterial chemoembolization therapy in prevention of hepatitis B-related hepatocellular carcinoma recurrence
    Yan Q, Ni J, Zhang GL, Yao X, Yuan WB, Zhou L, Zheng SS. Chin Med J (Engl). 2013 Mar;126(5):855-9.


  42. Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy
    Saitta C, Musolino C, Marabello G, Martino D, Leonardi MS, Pollicino T, Altavilla G, Raimondo G. Dig Liver Dis. 2013 Mar 11. pii: S1590-8658(13)00042-X. doi: 10.1016/j.dld.2013.01.022. [Epub ahead of print]


  43. Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus Infection
    Gatanaga H, Hayashida T, Tanuma J, Oka S. Clin Infect Dis. 2013 Mar 28. [Epub ahead of print]


  44. Ocular effects of pegylated interferon-? in patients with chronic hepatitis B
    Koktekir BE, Sumer S, Bakbak B, Gedik S, Gonul S, Ural O. Cutan Ocul Toxicol. 2013 Mar 12. [Epub ahead of print]


  45. Mother-to-Infant Transmission of Hepatitis B Virus Infection: Significance of Maternal Viral Load and Strategies for Intervention
    Wen WH, Chang MH, Zhao LL, Ni YH, Hsu HY, Wu JF, Chen PJ, Chen DS, Chen HL. J Hepatol. 2013 Feb 25. pii: S0168-8278(13)00137-2. doi: 10.1016/j.jhep.2013.02.015. [Epub ahead of print]


  46. Individualized treatment of HBeAg-negative CHB using peg-interferon alfa-2a as first-line and week 12 HBV-DNA\HBsAg stopping rule. A cost-effectiveness analysis
    Iannazzo S, Coco B, Brunetto MR, Rossetti F, Caputo A, Latour A, Espinos B, Bonino F.


  47. Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients
    Wang GQ, Ding YP, Dong YH. J Viral Hepat. 2013 Apr;20 Suppl 1:9-17. doi: 10.1111/jvh.12059.


  48. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil
    Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H. J Viral Hepat. 2013 Apr;20 Suppl 1:40-5. doi: 10.1111/jvh.12062.


  49. Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy
    Liu M, Cai H, Yi W. J Viral Hepat. 2013 Apr;20 Suppl 1:65-70. doi: 10.1111/jvh.12066.


  50. Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil
    Li Y, Zhang Y, Wang JP, Lian JQ, Bai XF. J Viral Hepat. 2013 Apr;20 Suppl 1:46-51. doi: 10.1111/jvh.12063.


  51. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study
    Huang Z, Zhao Z, Zheng Y, Peng L, Lin C, Deng H, Gao Z. J Viral Hepat. 2013 Apr;20 Suppl 1:52-7. doi: 10.1111/jvh.12064.


  52. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis
    Han Z, Shi Y, Zhu J, Chen Y, Yin F, Xia L, Luo G, Gao Z, Liu J, Jia G, Li C, Zhou X, Han Y. J Viral Hepat. 2013 Apr;20 Suppl 1:58-64. doi: 10.1111/jvh.12065.


  53. IL28B Polymorphism Correlates with Active Hepatitis in Patients with HBeAg-Negative Chronic Hepatitis B
    Lee IC, Lin CH, Huang YH, Huo TI, Su CW, Hou MC, Huang HC, Lee KC, Chan CC, Lin MW, Lin HC, Lee SD. PLoS One. 2013;8(2):e58071. doi: 10.1371/journal.pone.0058071. Epub 2013 Feb 28.


  54. Reduction of hepatitis B surface antigen levels and HBsAg seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy
    Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Hepatology. 2013 Mar 6. doi: 10.1002/hep.26376. [Epub ahead of print]


  55. Differential Plasma MicroRNA Profiles in HBeAg Positive and HBeAg Negative Children with Chronic Hepatitis B
    Winther TN, Bang-Berthelsen CH, Heiberg IL, Pociot F, Hogh B. PLoS One. 2013;8(3):e58236. doi: 10.1371/journal.pone.0058236. Epub 2013 Mar 4.


  56. Efficacy of Entecavir Treatment for up to 5 Years in Nucleos(t)ide-Naïve Chronic Hepatitis B Patients in Real Life
    Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y. Int J Med Sci. 2013;10(4):427-33. doi: 10.7150/ijms.5472. Epub 2013 Mar 1.


  57. Acute Hepatitis B in an Urban Tertiary Care Hospital in the United States: A Cohort Evaluation
    Sharif O, Krishnan PV, Thekdi AD, Gordon SC. J Clin Gastroenterol. 2013 Mar 6. [Epub ahead of print]


  58. Abnormal regional homogeneity of resting-state brain activity in patients with HBV-related cirrhosis without overt hepatic encephalopathy
    Lv XF, Qiu YW, Tian JZ, Xie CM, Han LJ, Su HH, Liu ZY, Peng JP, Lin CL, Wu MS, Jiang GH, Zhang XL. Liver Int. 2013 Mar;33(3):375-83. doi: 10.1111/liv.12096.


  59. Cost-minimization analysis of the U.S. Army accession screening and immunization program
    Tzeng J, Jankosky C, Hughes H. Mil Med. 2012 Dec;177(12):1508-12.


  60. Association of cytokine gene polymorphisms and serum concentrations with the outcome of chronic hepatitis B
    Conde SR, Feitosa RN, Freitas FB, Hermes RB, Demachki S, Araújo MT, Soares MC, Ishak R, Vallinoto AC. Cytokine. 2013 Feb 5. pii: S1043-4666(13)00034-3. doi: 10.1016/j.cyto.2013.01.004. [Epub ahead of print]


  61. Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C
    Sturm N, Marlu A, Arvers P, Zarski JP, Leroy V. Liver Int. 2013 Mar;33(3):428-38. doi: 10.1111/liv.12092.


  62. Chronic hepatitis B: What should be the goal for new therapies?
    Block TM, Gish R, Guo H, Mehta A, Cuconati A, Thomas London W, Guo JT. Antiviral Res. 2013 Feb 4. pii: S0166-3542(13)00021-1. doi: 10.1016/j.antiviral.2013.01.006. [Epub ahead of print]


  63. Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection
    Kondo Y, Ninomiya M, Kakazu E, Kimura O, Shimosegawa T. ISRN Gastroenterol. 2013;2013:935295. doi: 10.1155/2013/935295. Epub 2013 Jan 16.


  64. Does hepatitis B treatment reduce the incidence of hepatocellular carcinoma?
    Sherman M. Hepatology. 2013 Feb 11. doi: 10.1002/hep.26317. [Epub ahead of print]


  65. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients
    Tsuge M, Murakami E, Imamura M, Abe H, Miki D, Hiraga N, Takahashi S, Ochi H, Nelson Hayes C, Ginba H, Matsuyama K, Kawakami H, Chayama K. J Gastroenterol. 2013 Feb 9. [Epub ahead of print]


  66. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma
    Lao XM, Luo G, Ye LT, Luo C, Shi M, Wang D, Guo R, Chen M, Li S, Lin X, Yuan Y. Liver Int. 2013 Jan 12. doi: 10.1111/liv.12112. [Epub ahead of print]


  67. Hepatitis B
    Tong MJ, Trieu J. J Dig Dis. 2013 Feb 21. doi: 10.1111/1751-2980.12051. [Epub ahead of print]


  68. Towards complete eradication of hepatitis B infection from perinatal transmission: review of the mechanisms of in utero infection and the use of antiviral treatment during pregnancy
    Cheung KW, Seto MT, Wong SF. Eur J Obstet Gynecol Reprod Biol. 2013 Mar 4. pii: S0301-2115(13)00087-0. doi: 10.1016/j.ejogrb.2013.02.001. [Epub ahead of print]


  69. Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation
    Seo JY, Kim W, Kwon JH, Jin EH, Yu SJ, Kim HY, Jung YJ, Kim D, Kim YJ, Yoon JH, Lee HS. Liver Int. 2013 Jan 30. doi: 10.1111/liv.12132. [Epub ahead of print]


  70. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure
    Duan XZ, Liu FF, Tong JJ, Yang HZ, Chen J, Liu XY, Mao YL, Xin SJ, Hu JH. World J Gastroenterol. 2013 Feb 21;19(7):1104-10. doi: 10.3748/wjg.v19.i7.1104.


  71. Use of the International Classification of Diseases, 9th revision, coding in identifying chronic hepatitis B virus infection in health system data: implications for national surveillance
    Mahajan R, Moorman AC, Liu SJ, Rupp L, Klevens RM; for the Chronic Hepatitis Cohort Study (CHeCS) investigators*. J Am Med Inform Assoc. 2013 Mar 5. [Epub ahead of print]


  72. Expression of Interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection
    Du WJ, Zhen JH, Zeng ZQ, Zheng ZM, Xu Y, Qin LY, Chen SJ. Diagn Pathol. 2013 Feb 28;8:40. doi: 10.1186/1746-1596-8-40.


  73. A randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal post-liver transplant
    Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, Flaherty J, Dinh P, Rossi S, Subramanian GM, Spivey J. Liver Transpl. 2013 Feb 27. doi: 10.1002/lt.23628. [Epub ahead of print]


  74. Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection
    Su TH, Liu CJ, Tseng TC, Liu CH, Yang HC, Chen CL, Chen PJ, Kao JH, Chen DS. PLoS One. 2013;8(2):e55916. doi: 10.1371/journal.pone.0055916. Epub 2013 Feb 20.


  75. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates
    Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus PW. Liver Transpl. 2013 Mar;19(3):268-74. doi: 10.1002/lt.23600.


  76. Prevention of mother-to-child transmission of hepatitis B virus (HBV) during pregnancy and the puerperium: Current standards of care
    Giles ML, Grace R, Tai A, Michalak K, Walker SP. Aust N Z J Obstet Gynaecol. 2013 Mar 4. doi: 10.1111/ajo.12061. [Epub ahead of print]


  77. NK cells: a double-edged sword in chronic hepatitis B virus infection
    Maini MK, Peppa D. Front Immunol. 2013;4:57. doi: 10.3389/fimmu.2013.00057. Epub 2013 Mar 1.


  78. Diagnostic difficulties, therapeutic strategies, and performance of scoring systems in patients with autoimmune hepatitis and concurrent hepatitis B/C
    Efe C, Wahlin S, Ozaslan E, Purnak T, Muratori L, Quarneti C, Tatar G, Simsek H, Muratori P, Schiano TD. Scand J Gastroenterol. 2013 Mar 1. [Epub ahead of print]


  79. Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine
    Lo AO, Wong VW, Wong GL, Chan HY, Cheung CM, Chan HL. Antivir Ther. 2013 Mar 5. doi: 10.3851/IMP2526. [Epub ahead of print]


  80. Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation?
    Takaki A, Yagi T, Yasunaka T, Sadamori H, Shinoura S, Umeda Y, Yoshida R, Sato D, Nobuoka D, Utsumi M, Yasuda Y, Nakayama E, Miyake Y, Ikeda F, Shiraha H, Nouso K, Fujiwara T, Yamamoto K. J Gastroenterol. 2013 Feb 23. [Epub ahead of print]


  81. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients
    Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, Netto-Cardoso AC, Lada O, Batrla R, Krause F, Asselah T, Marcellin P. J Hepatol. 2013 Jan 28. pii: S0168-8278(13)00075-5. doi: 10.1016/j.jhep.2013.01.028. [Epub ahead of print]


  82. Invasive fungal infections secondary to acute-on-chronic liver failure: a retrospective study
    Lin LN, Zhu Y, Che FB, Gu JL, Chen JH. Mycoses. 2013 Feb 1. doi: 10.1111/myc.12044. [Epub ahead of print]


  83. Infectivity of blood products from donors with occult hepatitis B virus infection
    Allain JP, Mihaljevic I, Gonzalez-Fraile MI, Gubbe K, Holm-Harritshøj L, Garcia JM, Brojer E, Erikstrup C, Saniewski M, Wernish L, Bianco L, Ullum H, Candotti D, Lelie N, Gerlich WH, Chudy M. Transfusion. 2013 Jan 30. doi: 10.1111/trf.12096. [Epub ahead of print]


  84. Evolving Frequency and Outcomes of Liver Transplantation Based on Etiology of Liver Disease
    Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Transplantation. 2013 Jan 30. [Epub ahead of print]


  85. Comparative Efficacy of Oral Nucleoside or Nucleotide Analog Monotherapy Used in Chronic Hepatitis B: A Mixed-Treatment Comparison Meta-analysis
    Wiens A, Lenzi L, Venson R, Correr CJ, Rotta I, Pedroso ML, Pontarolo R. Pharmacotherapy. 2013 Feb;33(2):144-51. doi: 10.1002/phar.1188. Epub 2013 Jan 28.


  86. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis b with high baseline viral load (? 9 log10 copies/mL)
    Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, Martins EB, Yee LJ, Flaherty JF, Kitrinos KM, Rustgi VK, Marcellin P. Hepatology. 2013 Jan 30. doi: 10.1002/hep.26277. [Epub ahead of print]


  87. Efficacy of 3 years of adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance
    Song MN, Hong MZ, Luo DQ, Huang WQ, Min F, Fan RH, Wu WB, Zhang L. World J Hepatol. 2012 Dec 27;4(12):389-93. doi: 10.4254/wjh.v4.i12.389.


  88. Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: A meta-analysis
    Huang R, Hao Y, Zhang J, Wu C. Hepatol Res. 2013 Jan 10. doi: 10.1111/hepr.12058. [Epub ahead of print]


  89. IL21 and IL21R polymorphisms and their interactive effects on serum IL-21 and IgE levels in patients with chronic hepatitis B virus infection
    Li N, Zhu Q, Li Z, Han Q, Chen J, Lv Y, Wang Y, Zeng X, Chen Y, Yang C, Liu Z. Hum Immunol. 2013 Jan 24. pii: S0198-8859(13)00016-5. doi: 10.1016/j.humimm.2013.01.005. [Epub ahead of print]


  90. The use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients
    Ali S, Mealing S, Hawkins N, Lescrauwaet B, Bjork S, Mantovani L, Lampertico P. BMJ Open. 2013 Jan 24;3(1). pii: e001309. doi: 10.1136/bmjopen-2012-001309. Print 2013.


  91. Hepatitis B testing and access to care among racial and ethnic minorities in selected communities across the United States, 2009-2010
    Hu DJ, Xing J, Tohme RA, Liao Y, Pollack H, Ward JW, Holmberg SD. Hepatology. 2013 Jan 28. doi: 10.1002/hep.26286. [Epub ahead of print]


  92. Evaluation of seven noninvasive models in staging liver fibrosis in patients with chronic hepatitis B virus infection
    Ma J, Jiang Y, Gong G. Eur J Gastroenterol Hepatol. 2013 Jan 24. [Epub ahead of print]


  93. Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease
    Kwak MS, Kim D, Chung GE, Kang SJ, Park MJ, Kim YJ, Yoon JH, Lee HS. Clin Mol Hepatol. 2012 Dec;18(4):383-90. doi: 10.3350/cmh.2012.18.4.383. Epub 2012 Dec 21.


  94. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China
    Sun Z, Chen T, Thorgeirsson SS, Zhan Q, Chen J, Park JH, Lu P, Hsia CC, Wang N, Xu L, Lu L, Huang F, Zhu Y, Lu J, Ni Z, Zhang Q, Wu Y, Liu G, Wu Z, Qu C, Gail MH. Carcinogenesis. 2013 Jan 14. [Epub ahead of print]


  95. Efficacy of pegylated interferon alpha2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy
    Zhang XQ, Zhang HY, You JP, Mao Q. Virol J. 2013 Jan 15;10(1):21. [Epub ahead of print]


  96. Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues
    Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. World J Gastroenterol. 2012 Dec 28;18(48):7149-57. doi: 10.3748/wjg.v18.i48.7149.


  97. Can mean platelet volume determine the severity of liver fibrosis or inflammation in patients with chronic hepatitis B?
    Ceylan B, Fincanci M, Yardimci C, Eren G, Tözalgan U, Müderriso?lu C, Pa?ao?lu E. Eur J Gastroenterol Hepatol. 2013 Jan 15. [Epub ahead of print]


  98. Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B
    Yun TJ, Jung JY, Kim CH, Um SH, An H, Seo YS, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS. World J Gastroenterol. 2012 Dec 21;18(47):6987-95. doi: 10.3748/wjg.v18.i47.6987.


  99. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures
    Kim YJ, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. World J Gastroenterol. 2012 Dec 21;18(47):6996-7002. doi: 10.3748/wjg.v18.i47.6996.


  100. Hepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis
    Mandalà M, Fagiuoli S, Francisci D, Bruno R, Merelli B, Pasulo L, Tondini C, Labianca R, Roila F. Crit Rev Oncol Hematol. 2013 Jan 10. pii: S1040-8428(12)00250-8. doi: 10.1016/j.critrevonc.2012.12.004. [Epub ahead of print]


  101. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D
    Boglione L, D'Avolio A, Cariti G, Gregori G, Burdino E, Baietto L, Cusato J, Ghisetti V, De Rosa FG, Perri GD. Liver Int. 2012 Dec 12. doi: 10.1111/liv.12091. [Epub ahead of print]


  102. Knowledge and Behaviors Toward Hepatitis B and the Hepatitis B Vaccine in the Laotian Community in Minnesota
    Xiong M, Nguyen RH, Strayer L, Chanthanouvong S, Yuan JM. J Immigr Minor Health. 2013 Jan 11. [Epub ahead of print]


  103. HBV infection increases the risk of pancreatic cancer: a meta-analysis
    Luo G, Hao NB, Hu CJ, Yong X, Lü MH, Cheng BJ, Zhang Y, Yang SM. Cancer Causes Control. 2013 Jan 10. [Epub ahead of print]


  104. Telbivudine on-treatment HBsAg loss in naive HBeAg negative chronic hepatitis B: a case report and brief review of the literature
    Bertino G, Ardiri AM, Calvagno GS, Bertino N, Ruggeri MI, Malaguarnera M, Malaguarnera G, Toro A, Di Carlo I. Clin Ter. 2012 Nov;163(6):e429-34.


  105. Clin Dev Immunol. 2012;2012:843134. doi: 10.1155/2012/843134. Epub 2012 Dec 13. Rapid Immunization Scheme for Spouses of Individuals Estabilished as Hepatitis B Carriers during Premarital Tests.
    Tosun S, Yücetürk M, Dönmez AB, Gündüz T.


  106. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance
    Zoulim F, Locarnini S. Liver Int. 2013 Feb;33 Suppl 1:116-24. doi: 10.1111/liv.12069.


  107. Impact of therapy on the outcome of chronic hepatitis B
    Liaw YF. Liver Int. 2013 Feb;33 Suppl 1:111-5. doi: 10.1111/liv.12057.


  108. Antiviral therapy for patients with chronic hepatitis B with multi-drug resistance to nucleoside analogues
    Ozeki I, Hige S, Karino Y, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Ohmura T, Sato T, Toyota J. Nihon Shokakibyo Gakkai Zasshi. 2013;110(1):44-55.


  109. IL28B GENOTYPE IS NOT USEFUL FOR PREDICTING TREATMENT OUTCOME IN ASIAN CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGYLATED-INTERFERON-α
    Holmes JA, Nguyen T, Ratnam D, Heerasing NM, Tehan JV, Bonanzinga S, Dev A, Bell S, Pianko S, Chen R, Visvanathan K, Hammond R, Iser D, Rusli F, Sievert W, Desmond PV, Bowden DS, Thompson AJ. J Gastroenterol Hepatol. 2013 Jan 9. doi: 10.1111/jgh.12110. [Epub ahead of print]


  110. The role of HBsAg quantification for monitoring natural history and treatment outcome
    Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. Liver Int. 2013 Feb;33 Suppl 1:125-32. doi: 10.1111/liv.12075.


  111. Outbreak of hepatitis B virus infections associated with assisted monitoring of blood glucose in an assisted living facility-virginia, 2010
    Bender TJ, Wise ME, Utah O, Moorman AC, Sharapov U, Drobeniuc J, Khudyakov Y, Fricchione M, White-Comstock MB, Thompson ND, Patel PR. PLoS One. 2012;7(12):e50012. doi: 10.1371/journal.pone.0050012. Epub 2012 Dec 26.


  112. Trends in viral hepatitis cost-effectiveness studies
    Saab S, Choi Y, Rahal H, Li K, Tong M. Am J Manag Care. 2012 Dec;18(12):790-8.


  113. Association of chronic liver disease with depression: a population-based study
    Lee K, Otgonsuren M, Younoszai Z, Mir HM, Younossi ZM. Psychosomatics. 2013 Jan;54(1):52-9. doi: 10.1016/j.psym.2012.09.005.


  114. Lack of association between hepatitis B virus pre-S mutations and recurrence after surgical resection in hepatocellular carcinoma
    Heo NY, Lee HC, Park YK, Park JW, Lim YS, Kim KM, Shim JH, Lee YJ. J Med Virol. 2013 Jan 7. doi: 10.1002/jmv.23502. [Epub ahead of print]


  115. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma
    Yim HJ, Seo YS, Yoon EL, Kim CW, Lee CD, Park SH, Lee MS, Park CK, Chae HB, Kim MY, Baik SK, Kim YS, Kim JH, Lee JI, Lee JW, Hong SP, Um SH. Liver Int. 2013 Feb;33(2):244-54. doi: 10.1111/liv.12036.


  116. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma
    Yang Y, Xia T, Li N, Zhang J, Yang Y, Cong W, Deng Q, Lan K, Zhou W. Protein Cell. 2013 Jan;4(1):71-81. doi: 10.1007/s13238-012-2067-9. Epub 2012 Dec 22.


  117. Study on noninvasive laboratory tests for fibrosis in chronic HBV infection and their evaluation
    Chen J, Liu C, Chen H, Liu Q, Yang B, Ou Q. J Clin Lab Anal. 2013 Jan;27(1):5-11. doi: 10.1002/jcla.21554. Epub 2013 Jan 4.


  118. Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy
    Kim BK, Oh HJ, Park JY, Kim do Y, Ahn SH, Han KH, Park Y, J Yoo E, Park YN, Kim SU. Liver Int. 2013 Feb;33(2):180-9. doi: 10.1111/liv.12020.


  119. Identification of risk factors associated with immunoprophylaxis failure to prevent the vertical transmission of hepatitis B virus
    Yin Y, Wu L, Zhang J, Zhou J, Zhang P, Hou H. J Infect. 2012 Dec 31. pii: S0163-4453(12)00389-1. doi: 10.1016/j.jinf.2012.12.008. [Epub ahead of print]


  120. Hepatitis B Screening in US Travelers Seen at the Boston Area Travel Medicine Network
    Chen LH, Barnett ED, Wilson ME, Macleod W, Yanni EA, Ooi W, Karchmer AW, Kogelman L, Marano N, Hamer DH. J Travel Med. 2013 Jan;20(1):29-36. doi: 10.1111/jtm.12002.


  121. IL17A gene polymorphisms, serum IL-17A and IgE levels, and hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection
    Li N, Zhu Q, Li Z, Han Q, Zhang G, Chen J, Lv Y, Xing F, Chen Y, Zeng X, Liu Z. Mol Carcinog. 2012 Dec 31. doi: 10.1002/mc.21992. [Epub ahead of print]


  122. Genetic variations of PD1 and TIM3 are differentially and interactively associated with the development of cirrhosis and HCC in patients with chronic HBV infection
    Li Z, Li N, Zhu Q, Zhang G, Han Q, Zhang P, Xun M, Wang Y, Zeng X, Yang C, Liu Z. Infect Genet Evol. 2013 Jan 2. pii: S1567-1348(12)00390-5. doi: 10.1016/j.meegid.2012.12.008. [Epub ahead of print]


  123. Trends in viral hepatitis cost-effectiveness studies
    Saab S, Choi Y, Rahal H, Li K, Tong M. Am J Manag Care. 2012 Dec;18(12):790-8.


  124. The Diversity and Management of Chronic Hepatitis B Virus Infections in the UK - A Wake up Call
    Tedder RS, Rodger AJ, Fries L, Ijaz S, Thursz M, Rosenberg W, Naoumov N, Banatvala J, Williams R, Dusheiko G, Chokshi S, Wong T, Rosenberg G, Moreea S, Bassendine M, Jacobs M, Mills PR, Mutimer D, Ryder S, Bathgate A, Hussaini H, Dillon J, Wright M, Bird G, Collier J, Anderson M, Johnson A; for the CUSHIB Study Group. Clin Infect Dis. 2012 Dec 7. [Epub ahead of print]


  125. Hepatitis B screening: who to target? A French Sexually Transmitted Infection Clinic Experience
    Spenatto N, Boulinguez S, Mularczyk M, Molinier L, Bureau C, Saune K, Viraben R. J Hepatol. 2012 Dec 5. pii: S0168-8278(12)00914-2. doi: 10.1016/j.jhep.2012.11.044. [Epub ahead of print]


  126. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis
    Lin CW, Lin CC, Mo LR, Chang CY, Perng DS, Hsu CC, Lo GH, Chen YS, Yen YC, Hu JT, Yu ML, Lee PH, Lin JT, Yang SS. J Hepatol. 2012 Dec 6. pii: S0168-8278(12)00916-6. doi: 10.1016/j.jhep.2012.11.045. [Epub ahead of print]


  127. Long-term Hepatitis B Surface Antigen (HBsAg) Kinetics during Nucleoside/Nucleotide Analogue Therapy: Finite Treatment Duration Unlikely
    Chevaliez S, Hézode C, Bahrami S, Grare M, Pawlotsky JM. J Hepatol. 2012 Dec 3. pii: S0168-8278(12)00909-9. doi: 10.1016/j.jhep.2012.11.039. [Epub ahead of print]


  128. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
    Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Lancet. 2012 Dec 7. pii: S0140-6736(12)61425-1. doi: 10.1016/S0140-6736(12)61425-1. [Epub ahead of print]


  129. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma
    Jiang DK, Sun J, Cao G, Liu Y, Lin D, Gao YZ, Ren WH, Long XD, Zhang H, Ma XP, Wang Z, Jiang W, Chen TY, Gao Y, Sun LD, Long JR, Huang HX, Wang D, Yu H, Zhang P, Tang LS, Peng B, Cai H, Liu TT, Zhou P, Liu F, Lin X, Tao S, Wan B, Sai-Yin HX, Qin LX, Yin J, Liu L, Wu C, Pei Y, Zhou YF, Zhai Y, Lu PX, Tan A, Zuo XB, Fan J, Chang J, Gu X, Wang NJ, Li Y, Liu YK, Zhai K, Zhang H, Hu Z, Liu J, Yi Q, Xiang Y, Shi R, Ding Q, Zheng W, Shu XO, Mo Z, Shugart YY, Zhang XJ, Zhou G, Shen H, Zheng SL, Xu J, Yu L. Nat Genet. 2012 Dec 16;45(1):72-5. doi: 10.1038/ng.2483. Epub 2012 Dec 16.


  130. Cumulative viral evolutionary changes in chronic hepatitis B virus infection precedes hepatitis B e antigen seroconversion
    Cheng Y, Guindon S, Rodrigo A, Wee LY, Inoue M, Thompson AJ, Locarnini S, Lim SG. Gut. 2012 Dec 15. [Epub ahead of print]


  131. Influence of Information Sources on Hepatitis B Screening Behavior and Relevant Psychosocial Factors Among Asian Immigrants
    Tanaka M, Strong C, Lee S, Juon HS. J Immigr Minor Health. 2012 Dec 13. [Epub ahead of print]


  132. Safety of lamivudine treatment for chronic hepatitis B in early pregnancy
    Yi W, Liu M, Cai HD. World J Gastroenterol. 2012 Dec 7;18(45):6645-50. doi: 10.3748/wjg.v18.i45.6645.


  133. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs
    Petersen J, Buti M. Expert Rev Gastroenterol Hepatol. 2012 Dec;6(6):683-94. doi: 10.1586/egh.12.52.


  134. A Predictive Scoring System for the Seroclearance of HBsAg in HBeAg-seronegative Chronic Hepatitis B Patients with Genotype B or C Infection
    Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, Wang LY, You SL, Hsiao CK, Yang HI, Chen CJ. J Hepatol. 2012 Dec 12. pii: S0168-8278(12)00954-3. doi: 10.1016/j.jhep.2012.12.006. [Epub ahead of print]


  135. Hepatitis B and C in liver transplantation: new strategies to combat the enemies
    Beckebaum S, Kabar I, Cicinnati VR. Rev Med Virol. 2012 Dec 13. doi: 10.1002/rmv.1734. [Epub ahead of print]


  136. The survival benefit of liver transplantation for hepatocellular carcinoma patients with hepatitis B virus infection and cirrhosis
    Zhang Q, Chen X, Zang Y, Zhang L, Chen H, Wang L, Niu Y, Ren X, Shen Z, Shang L. PLoS One. 2012;7(12):e50919. doi: 10.1371/journal.pone.0050919. Epub 2012 Dec 7.


  137. Evaluation of Hepatitis B Viraemia Levels in Patients with HBeAg-negative Chronic Hepatitis B Virus Infection
    Atay AE, Seven G, Yalcin K, Pasa S, Degertekin H. J Int Med Res. 2012;40(5):1891-6.


  138. Antibody persistence and the effect of a booster dose given 5, 10 or 15years after vaccinating preadolescents with a recombinant hepatitis B vaccine
    Gilca V, De Serres G, Boulianne N, Murphy D, De Wals P, Ouakki M, Trudeau G, Massé R, Dionne M. Vaccine. 2012 Dec 1. pii: S0264-410X(12)01630-1. doi: 10.1016/j.vaccine.2012.11.037. [Epub ahead of print]


  139. Liver stiffness measurement in cirrhotic patient - Implications of disease activity and treatment efficacy
    Xu HW, Lu SN, Hung CH, Chang KC, Hu TH, Wang JH. Kaohsiung J Med Sci. 2012 Dec;28(12):641-8. doi: 10.1016/j.kjms.2012.04.032. Epub 2012 Aug 1.


  140. The Frequency of Adjusted Renal Dosing of Tenofovir DF and Its Effects on Patient Outcomes
    Langness JA, Hindman JT, Johnson SC, Kiser JJ. J Pharm Pract. 2012 Dec 2. [Epub ahead of print]


  141. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection
    Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Hepatology. 2012 Dec 5. doi: 10.1002/hep.26180. [Epub ahead of print]


  142. Atypical serological profiles in hepatitis B virus infection
    Pondé RA. Eur J Clin Microbiol Infect Dis. 2012 Nov 29. [Epub ahead of print]


  143. Hepatitis B-core Antibody Positive Donors in Liver Transplantation and Their Impact on Graft Survival: Evidence From The Liver Match Cohort Study
    Angelico M, Nardi A, Marianelli T, Caccamo L, Romagnoli R, Tisone G, Pinna AD, Avolio AW, Fagiuoli S, Burra P, Strazzabosco M, Costa AN. J Hepatol. 2012 Nov 27. pii: S0168-8278(12)00894-X. doi: 10.1016/j.jhep.2012.11.025. [Epub ahead of print]


  144. Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study
    Lee SJ, Yim HJ, Hwang SG, Seo YS, Kim JH, Yoon EL, Lee JM, Kim BH, Park SJ, Park YM, Kim HS, Lee SH, Ahn SH, Lee JI, Lee JW, Kim IH, Kim HS, Hong SP. Scand J Gastroenterol. 2012 Nov 30. [Epub ahead of print]


  145. Reactivation of hepatitis viruses following immunomodulationg systemic chemotherapy
    Watanabe T, Tanaka Y. Hepatol Res. 2012 Oct 30. doi: 10.1111/hepr.12014. [Epub ahead of print]


  146. The Short-Term Efficacy of Entecavir in Lamivudine-Resistant Chronic Hepatitis B: Influence of Sequential Adefovir-Refractoriness
    Kim JH, Kim YS, Jung YK, Kim YS, Kwon OS, Ku YS, Choi DJ, Kim JH. Hepatogastroenterology. 2012 Nov 28;60(125). doi: 10.5754/hge12917. [Epub ahead of print]


  147. Reactivation of Hepatitis B Virus in Patients Receiving Chemotherapy
    Ikeda M. Jpn J Clin Oncol. 2012 Nov 25. [Epub ahead of print]


  148. Prevalence and time course of hepatitis B virus infection in patients with systemic lupus erythematosus under immunosuppressive therapy
    Watanabe R, Ishii T, Nakamura K, Shirai T, Tajima Y, Fujii H, Harigae H. Mod Rheumatol. 2012 Nov 21. [Epub ahead of print]


  149. The Efficacy of Adefovir Plus Entecavir Combination Therapy in Patients with Chronic Hepatitis B Refractory to Both Lamivudine and Adefovir
    Cho Y, Lee DH, Chung KH, Jin E, Lee JH, Cho EJ, Yu SJ, Kim JW, Jeong SH, Yoon JH, Lee HS, Kim CY, Kim YJ. Dig Dis Sci. 2012 Nov 23. [Epub ahead of print]


  150. Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients
    Pan CQ, Hu KQ, Tsai N. Antivir Ther. 2012 Nov 23. doi: 10.3851/IMP2481. [Epub ahead of print]


  151. Influence of Age and HBeAg Status on the Correlation Between HBV DNA and Hepatic Inflammation and Fibrosis in Chronic Hepatitis B Patients
    Bai H, Liu H, Chen X, Xu C, Dou X. Dig Dis Sci. 2012 Nov 22. [Epub ahead of print]


  152. Occult hepatitis B virus and the risk for chronic liver disease: A meta-analysis
    Covolo L, Pollicino T, Raimondo G, Donato F. Dig Liver Dis. 2012 Nov 9. pii: S1590-8658(12)00380-5. doi: 10.1016/j.dld.2012.09.021. [Epub ahead of print]


  153. Managing chronic hepatitis B - The role of the GP
    Wallace J, Hajarizadeh B, Richmond J, McNally S, Pitts M. Aust Fam Physician. 2012 Nov;41(11):893-8.


  154. Effectiveness of a culturally integrated liver cancer education in improving HBV knowledge among Asian Americans
    Juon HS, Park BJ. Prev Med. 2012 Nov 15. pii: S0091-7435(12)00557-9. doi: 10.1016/j.ypmed.2012.11.003. [Epub ahead of print]


  155. Association of chronic viral hepatitis B with insulin resistance
    Lee JG, Lee S, Kim YJ, Cho BM, Park JS, Kim HH, Cheong J, Jeong DW, Lee YH, Cho YH, Bae MJ, Choi EJ. World J Gastroenterol. 2012 Nov 14;18(42):6120-6. doi: 10.3748/wjg.v18.i42.6120.


  156. Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy
    Wang YH, Fan L, Wang L, Zhang R, Xu J, Fang C, Li JY, Xu W. Support Care Cancer. 2012 Nov 15. [Epub ahead of print]


  157. Hepatitis B virus status and the risk of pancreatic cancer: a meta-analysis
    Wang Y, Yang S, Song F, Cao S, Yin X, Xie J, Tu X, Xu J, Xu X, Dong X, Lu Z. Eur J Cancer Prev. 2012 Nov 16. [Epub ahead of print]


  158. Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long-term entecavir 0.5 mg daily in routine clinical practice
    Liu A, Ha NB, Lin B, Yip B, Trinh HN, Nguyen HA, Nguyen KK, Ahmed A, Garcia G, Nguyen MH. Eur J Gastroenterol Hepatol. 2012 Nov 18. [Epub ahead of print]


  159. Community Health Education at Student-Run Clinics Leads to Sustained Improvement in Patients' Hepatitis B Knowledge
    Ouyang D, Yuan N, Sheu L, Lau G, Chen C, Lai CJ. J Community Health. 2012 Nov 18. [Epub ahead of print]


  160. Serum hepatitis B surface antigen is correlated with intrahepatic total HBV DNA and cccDNA in treatment-Naïve patients with chronic hepatitis B but not in patients with HBV related hepatocellular carcinoma
    Wang M, Qiu N, Lu S, Xiu D, Yu J, Wang XT, Lu F, Li T, Liu X, Zhuang H. J Med Virol. 2012 Nov 20. doi: 10.1002/jmv.23461. [Epub ahead of print]


  161. How to manage HBeAg-negative chronic HBV infection with normal alanine aminotransferase levels in clinical practice?
    Puoti C. Eur J Intern Med. 2012 Nov 17. pii: S0953-6205(12)00286-5. doi: 10.1016/j.ejim.2012.10.013. [Epub ahead of print]


  162. Long-term treatment efficacy and safety of clevudine therapy in naïve patients with chronic hepatitis B
    Choung BS, Kim IH, Jeon BJ, Lee S, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG. Gut Liver. 2012 Oct;6(4):486-92. doi: 10.5009/gnl.2012.6.4.486. Epub 2012 Oct 18.


  163. Safety and efficacy of four steroid-minimization protocols in liver transplant recipients: 3-year follow-up in a single center
    Hu AB, Wu LW, Tai Q, He XS, Zhu XF. J Dig Dis. 2012 Oct 31. doi: 10.1111/1751-2980.12008. [Epub ahead of print]


  164. Prevalence and Factors Associated with Hepatitis B Immunization and Infection among Men Who Have Sex with Men in Beijing, China
    Wang C, Wang Y, Huang X, Li X, Zhang T, Song M, Wu L, Du J, Lu X, Shao S, Zhao F, Ball MA, Wu H, Wang W. PLoS One. 2012;7(10):e48219. doi: 10.1371/journal.pone.0048219. Epub 2012 Oct 25.


  165. Natural Killer Cells Are Characterized by the Concomitantly Increased Interferon-? and Cytotoxicity in Acute Resolved Hepatitis B Patients
    Zhao J, Li Y, Jin L, Zhang S, Fan R, Sun Y, Zhou C, Shang Q, Li W, Zhang Z, Wang FS. PLoS One. 2012;7(11):e49135. doi: 10.1371/journal.pone.0049135. Epub 2012 Nov 1.


  166. Safety and Efficacy of Subcutaneous Hepatitis B Immunoglobulin After Liver Transplantation: An Open Single-Arm Prospective Study
    Di Costanzo GG, Lanza AG, Picciotto FP, Imparato M, Migliaccio C, De Luca M, Scuderi V, Tortora R, Cordone G, Utech W, Calise F. Am J Transplant. 2012 Nov 8. doi: 10.1111/j.1600-6143.2012.04319.x. [Epub ahead of print]


  167. Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B
    Ikeda K, Izumi N, Tanaka E, Yotsuyanagi H, Takahashi Y, Fukushima J, Kondo F, Fukusato T, Koike K, Hayashi N, Kumada H. Hepatol Res. 2012 Nov 2. doi: 10.1111/j.1872-034X.2012.01115.x. [Epub ahead of print]


  168. Changing epidemiology of Hepatitis B and migration--a comparison of six Northern and North-Western European countries
    Chu JJ, Wörmann T, Popp J, Pätzelt G, Akmatov MK, Krämer A, Reintjes R. Eur J Public Health. 2012 Jun 8. [Epub ahead of print]


  169. Elecsys Hepatitis B Surface Antigen Quantitative Assay: Performance Evaluation and Correlation with Hepatitis B Virus DNA during 96 Weeks of Follow-up in Chronic Hepatitis B Patients
    Lee HJ, Kim SY, Lee SM, Heo J, Kim HH, Chang CL, Lee EY, Son HC. Ann Lab Med. 2012 Nov;32(6):420-5. doi: 10.3343/alm.2012.32.6.420. Epub 2012 Oct 17.


  170. High Genetic Barrier Nucleos(t)ide Analogue(s) for Prophylaxis From Hepatitis B Virus Recurrence After Liver Transplantation: A Systematic Review
    Cholongitas E, Papatheodoridis GV. Am J Transplant. 2012 Nov 8. doi: 10.1111/j.1600-6143.2012.04315.x. [Epub ahead of print]


  171. HBVdb: a knowledge database for Hepatitis B Virus
    Hayer J, Jadeau F, Deléage G, Kay A, Zoulim F, Combet C. Nucleic Acids Res. 2012 Nov 3. [Epub ahead of print]


  172. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis
    Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Niinomi T, Yasuda S, Andou Y, Yamamoto K, Tanaka J. J Hepatol. 2012 Oct 30. pii: S0168-8278(12)00826-4. doi: 10.1016/j.jhep.2012.10.025. [Epub ahead of print]


  173. Infectious Disease Burden and Vaccination Needs Among Asylees Versus Refugees -- District of Columbia
    Chai SJ, Davies-Cole J, Cookson ST. Clin Infect Dis. 2012 Nov 1. [Epub ahead of print]


  174. Pretreatment viral DNA stratifies mortality risk in patients receiving antiviral therapy for severe acute exacerbation of chronic hepatitis B
    Hsu YC, Wu CY, Chang CY, Tai CM, Tseng CH, Perng DS, Mo LR, Lin JT. Antivir Ther. 2012 Nov 6. doi: 10.3851/IMP2435. [Epub ahead of print]


  175. Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients
    Orito E, Fujiwara K, Kanie H, Ban T, Yamada T, Hayashi K. World J Gastroenterol. 2012 Oct 21;18(39):5570-5. doi: 10.3748/wjg.v18.i39.5570.


  176. The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis
    Isgro G, Calvaruso V, Andreana L, Luong TV, Garcovich M, Manousou P, Alibrandi A, Maimone S, Marelli L, Davies N, Patch D, Dhillon AP, Burroughs AK. J Gastroenterol. 2012 Nov 3. [Epub ahead of print]


  177. Antiviral therapy for hepatitis B virus-related decompensated cirrhosis
    Wang JY. J Dig Dis. 2012 Nov;13(11):555-7. doi: 10.1111/j.1751-2980.2012.00630.x


  178. Genotype/subgenotype distribution of hepatitis B virus among hemodialysis patients with chronical hepatitis B
    Sayan M, Dogan C. Ann Hepatol. 2012 Nov;11(6):849-54.


  179. Internist diagnosis and management of chronic hepatitis B virus infection
    McMahon BJ, Block J, Haber B, London T, McHugh JA, Perrillo R, Neubauer R. Am J Med. 2012 Nov;125(11):1063-7. doi: 10.1016/j.amjmed.2012.03.010.


  180. Role of Leptin Receptor (LEPR) Gene Polymorphisms and Haplotypes in Susceptibility to Hepatocellular Carcinoma in Subjects with Chronic Hepatitis B Virus Infection
    Li Z, Yuan W, Ning S, Li J, Zhai W, Zhang S. Mol Diagn Ther. 2012 Oct 23. [Epub ahead of print]


  181. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: Clonal evolution during lamivudine plus adefovir therapy
    Kim SS, Cho SW, Kim SO, Hong SP, Cheong JY. J Med Virol. 2012 Oct 23. doi: 10.1002/jmv.23440. [Epub ahead of print]


  182. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy
    Lee YH, Bae SC, Song GG. Clin Exp Rheumatol. 2012 Oct 30. [Epub ahead of print]


  183. Yield of Screening for Long-Term Complications Using the Children's Oncology Group Long-Term Follow-Up Guidelines
    Landier W, Armenian SH, Lee J, Thomas O, Wong FL, Francisco L, Herrera C, Kasper C, Wilson KD, Zomorodi M, Bhatia S. J Clin Oncol. 2012 Oct 22. [Epub ahead of print]


  184. Response to Higher Dose of Entecavir 1.0 mg Daily in Patients With Partial Response to Entecavir 0.5 mg Daily
    Ha NB, Ha NB, Trinh HN, Nguyen HA, Nguyen KK, Nguyen MH. J Clin Gastroenterol. 2012 Oct 17. [Epub ahead of print]


  185. Subgenotyping of genotype C hepatitis B virus: correcting misclassifications and identifying a novel subgenotype
    Shi W, Zhu C, Zheng W, Zheng W, Ling C, Carr MJ, Higgins DG, Zhang Z. PLoS One. 2012;7(10):e47271. doi: 10.1371/journal.pone.0047271. Epub 2012 Oct 15.


  186. Does chronic hepatitis B infection affect the clinical course of acute hepatitis A?
    Shin SR, Moh IH, Jung SW, Kim JB, Park SH, Kim HS, Jang MK, Lee MS. J Med Virol. 2012 Oct 16. doi: 10.1002/jmv.23433. [Epub ahead of print]


  187. Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B
    He Z, Wang J, Liu K, Huang H, Du Y, Lin Z, Cai M, Feng X. Clin Res Hepatol Gastroenterol. 2012 Oct 12. pii: S2210-7401(12)00173-8. doi: 10.1016/j.clinre.2012.05.012. [Epub ahead of print]


  188. Causes of death in patients with hepatitis B: A natural history cohort study in the United States
    Szpakowski JL, Tucker LY. Hepatology. 2012 Oct 18. doi: 10.1002/hep.26110. [Epub ahead of print]


  189. Electronic Messages Increase Hepatitis B Screening in At-Risk Asian American Patients: A Randomized, Controlled Trial
    Hsu L, Bowlus CL, Stewart SL, Nguyen TT, Dang J, Chan B, Chen MS Jr. Dig Dis Sci. 2012 Oct 17. [Epub ahead of print]


  190. Cytokine Levels and Histopathology in Chronic Hepatitis B and Chronic Hepatitis C
    Akcam FZ, Tigli A, Kaya O, Ciris M, Vural H. J Interferon Cytokine Res. 2012 Oct 15. [Epub ahead of print]


  191. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study
    Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. J Gastroenterol. 2012 Oct 12. [Epub ahead of print]


  192. Serum cytokine levels in chronic hepatitis B patients receiving peginterferon alpha-2a therapy
    Park Y, Park JY, Han KH, Kim HS. Hepatobiliary Pancreat Dis Int. 2012 Oct;11(5):499-506.


  193. Long-Term Efficacy and Safety of Lamivudine, Entecavir, and Tenofovir for Treatment of HBV-Related Cirrhosis
    Köklü S, Tuna Y, Gül?en MT, Demir M, Köksal AS, Koçkar MC, Aygün C, Coban S, Ozdil K, Ataseven H, Ak?n E, Pürnak T, Yüksel I, Ataseven H, Ibi? M, Y?ld?r?m B, Nadir I, Küçükazman M, Akbal E, Yüksel O, Ba?ar O. Clin Gastroenterol Hepatol. 2012 Oct 9. pii: S1542-3565(12)01157-3. doi: 10.1016/j.cgh.2012.10.003. [Epub ahead of print]


  194. The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation
    Tanaka T, Benmousa A, Marquez M, Therapondos G, Renner EL, Lilly LB. Clin Transplant. 2012 Sep;26(5):E561-9. doi: 10.1111/ctr.12022.


  195. De novo HBV infection in a Mayo Clinic hemodialysis population: Economic impact of reduced HBV testing and a call for changes in current US CDC guidelines on HBV testing protocols
    Onuigbo MA, Onuigbo NT. Hemodial Int. 2012 Oct;16 Suppl 1:S32-8. doi: 10.1111/j.1542-4758.2012.00748.x.


  196. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog
    Tseng TC, Kao JH. J Gastroenterol. 2012 Oct 24. [Epub ahead of print]


  197. The innate immune response to hepatitis B virus infection: Implications for pathogenesis and therapy
    Chang J, Block TM, Guo JT. Antiviral Res. 2012 Oct 13. pii: S0166-3542(12)00231-8. doi: 10.1016/j.antiviral.2012.10.001. [Epub ahead of print]


  198. Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients
    Jin YJ, Kim KM, Yoo DJ, Shim JH, Lee HC, Chung YH, Lee YS, Suh DJ. Virol J. 2012 Oct 18;9(1):239. [Epub ahead of print]


  199. Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
    Shao YY, Lu LC, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Br J Cancer. 2012 Oct 11. doi: 10.1038/bjc.2012.466. [Epub ahead of print]


  200. A Meta-Analysis of Nucleos(t)ide Analogues in Patients with Decompensated Cirrhosis Due to Hepatitis B
    Huang Y, Wu H, Wu S, Fu D, Ma Y, Shen X. Dig Dis Sci. 2012 Sep 30. [Epub ahead of print]


  201. High Frequency of Genotype D and Spontaneous Hepatitis B Virus Genomic Mutations Among Haitians in a Multiethnic North American Population
    Couto CA, Levy C, Morris CJ, Hill M, de Medina M, Sanborn MR, Cloherty GA, Schiff ER, Martin P. J Clin Gastroenterol. 2012 Oct 10. [Epub ahead of print]


  202. Predictors of the outcomes of acute-on-chronic hepatitis B liver failure
    Fan HL, Yang PS, Chen HW, Chen TW, Chan DC, Chu CH, Yu JC, Kuo SM, Hsieh CB. World J Gastroenterol. 2012 Sep 28;18(36):5078-83. doi: 10.3748/wjg.v18.i36.5078.


  203. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B
    Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, Cursaro C, Panno AM, Bernardi M, Brander C, Bihl F, Andreone P, Maini MK. J Hepatol. 2012 Oct 6. pii: S0168-8278(12)00761-1. doi: 10.1016/j.jhep.2012.09.029. [Epub ahead of print]


  204. Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis
    Iavarone M, Manini MA, Sangiovanni A, Fraquelli M, Forzenigo LV, Di Tommaso L, Aghemo A, Roncalli M, Ronchi G, Colombo M. Dig Liver Dis. 2012 Sep 26. pii: S1590-8658(12)00298-8. doi: 10.1016/j.dld.2012.08.009. [Epub ahead of print]


  205. Positive hepatitis B surface antigen tests due to recent vaccination: a persistent problem
    Rysgaard CD, Morris CS, Drees D, Bebber T, Davis SR, Kulhavy J, Krasowski MD. BMC Clin Pathol. 2012 Sep 24;12(1):15. [Epub ahead of print]


  206. Postvaccination serologic testing results for infants aged ?24 months exposed to hepatitis B virus at birth - United States, 2008-2011
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2012 Sep 28;61:768-71.


  207. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?
    Lee GH, Aung MO, Dan YY, Lee YM, Mak B, Low HC, Lim K, Thwin MA, Tan PS, Lim SG. J Med Virol. 2012 Sep 28. doi: 10.1002/jmv.23392. [Epub ahead of print]


  208. A comparison of human immunodeficiency virus, hepatitis?C virus, hepatitis?B virus, and human T-lymphotropic virus marker rates for directed versus volunteer blood donations to the American Red Cross during 2005 to 2010
    Dorsey KA, Moritz ED, Steele WR, Eder AF, Stramer SL. Transfusion. 2012 Sep 25. doi: 10.1111/j.1537-2995.2012.03904.x. [Epub ahead of print]


  209. Hepatitis B Virus Reactivation Associated with Anti-Neoplastic Therapy
    Yeo W, Farrell G, Chan HL. J Gastroenterol Hepatol. 2012 Sep 28. doi: 10.1111/j.1440-1746.2012.07280.x. [Epub ahead of print]


  210. Prediction of significant fibrosis and cirrhosis in hepatitis B e-antigen negative patients with chronic hepatitis B using routine parameters
    Wang Y, Xu MY, Zheng RD, Xian JC, Xu HT, Shi JP, Li SB, Qu Y, Dong YW, Lu LG. Hepatol Res. 2012 Sep 25. doi: 10.1111/j.1872-034X.2012.01094.x. [Epub ahead of print]


  211. Evaluation of Anti-HBV Drug Resistant Mutations Among Patients with Acute Symptomatic Hepatitis B in the United States
    Baxa DM, Thekdi AD, Golembieski A, Krishnan PV, Sharif O, Kizy A, Shetron-Rama L, Jovanovich J, Chappell BJ, Snow-Lampart A, Borroto-Esoda K, Gordon SC. J Hepatol. 2012 Sep 26. pii: S0168-8278(12)00745-3. doi: 10.1016/j.jhep.2012.09.014. [Epub ahead of print]


  212. Are novel combination therapies needed for chronic hepatitis B?
    Zoulim F. Antiviral Res. 2012 Sep 19. pii: S0166-3542(12)00203-3. doi: 10.1016/j.antiviral.2012.09.006. [Epub ahead of print]


  213. Dating the origin and dispersal of hepatitis B virus infection in humans and primates
    Paraskevis D, Magiorkinis G, Magiorkinis E, Ho SY, Belshaw R, Allain JP, Hatzakis A. Hepatology. 2012 Sep 17. doi: 10.1002/hep.26079. [Epub ahead of print]


  214. Hepatitis B in pregnancy
    Borgia G, Carleo MA, Gaeta GB, Gentile I. World J Gastroenterol. 2012 Sep 14;18(34):4677-83.


  215. Genotype D of hepatitis B virus and its subgenotypes: An update
    Yousif M, Kramvis A. Hepatol Res. 2012 Sep 16. doi: 10.1111/j.1872-034X.2012.01090.x. [Epub ahead of print]


  216. Revaccination with Fendrix(®) or HBVaxPro(®) results in better response rates than does revaccination with three doses of Engerix-B(®) in previous non-responders
    Hoebe CJ, Vermeiren AP, Dukers-Muijrers NH. Vaccine. 2012 Sep 11. pii: S0264-410X(12)01293-5. doi: 10.1016/j.vaccine.2012.08.074. [Epub ahead of print]


  217. Viral load and ALT correlate with serologic response in chronic hepatitis B patients treated with entecavir
    Wang CC, Tseng KC, Peng CY, Hsieh TY, Lin CL, Su TH, Tseng TC, Hsu CS, Lin HH, Kao JH. J Gastroenterol Hepatol. 2012 Sep 18. doi: 10.1111/j.1440-1746.2012.07269.x. [Epub ahead of print]


  218. Knowledge, attitudes and barriers regarding vaccination against hepatitis A and B in patients with chronic hepatitis C virus infection: a survey of family medicine and internal medicine physicians in the United States
    Tenner CT, Herzog K, Chaudhari S, Bini EJ, Weinshel EH. Int J Clin Pract. 2012 Oct;66(10):1009-13. doi: 10.1111/ijcp.12013.


  219. Viral hepatitis: Global goals for vaccination
    Lavanchy D. J Clin Virol. 2012 Sep 20. pii: S1386-6532(12)00326-5. doi: 10.1016/j.jcv.2012.08.022. [Epub ahead of print]


  220. Hepatitis B and C virus infections as possible risk factor for pancreatic adenocarcinoma
    Fiorino S, Lorenzini S, Masetti M, Deleonardi G, Grondona AG, Silvestri T, Chili E, Del Prete P, Bacchi-Reggiani L, Cuppini A, Jovine E. Med Hypotheses. 2012 Sep 5. [Epub ahead of print]


  221. Management of chronic hepatitis B in pregnancy
    Han GR, Xu CL, Zhao W, Yang YF. World J Gastroenterol. 2012 Sep 7;18(33):4517-21.


  222. Young Chronic Hepatitis B Patients with Nucleos(t)ide Analogues-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation
    Tseng TC, Liu CJ, Su TH, Yang HC, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. J Infect Dis. 2012 Sep 10. [Epub ahead of print]


  223. What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients?
    Yan Y, Mai L, Zheng YB, Zhang SQ, Xu WX, Gao ZL, Ke WM. World J Gastroenterol. 2012 Sep 7;18(33):4604-9.


  224. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels
    Shin JW, Jung SW, Park BR, Kim CJ, Eum JB, Kim BG, Jeong ID, Bang SJ, Lee SH, Kim SR, Park NH. J Viral Hepat. 2012 Oct;19(10):724-31. doi: 10.1111/j.1365-2893.2012.01599.x. Epub 2012 Mar 15.


  225. The impact of new vaccine introduction on immunization and health systems: A review of the published literature
    Hyde TB, Dentz H, Wang SA, Burchett HE, Mounier-Jack S, Mantel CF; The New Vaccine Introduction Impact Published Literature Working Group. Vaccine. 2012 Aug 29. [Epub ahead of print]


  226. Cost-Effectiveness of Hepatitis B Vaccination in Adults With Diagnosed Diabetes
    Hoerger TJ, Schillie S, Wittenborn JS, Bradley CL, Zhou F, Byrd K, Murphy TV. Diabetes Care. 2012 Aug 28. [Epub ahead of print]


  227. High Frequency of Recurrent Viremia After Hepatitis B e Antigen Seroconversion and Consolidation Therapy
    Chaung KT, Ha NB, Trinh HN, Garcia RT, Nguyen HA, Nguyen KK, Garcia G, Ahmed A, Keeffe EB, Nguyen MH. J Clin Gastroenterol. 2012 Aug 30. [Epub ahead of print]


  228. Serum hepatitis B surface antigen levels help predict disease progression in patients with low HBV loads
    Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Hsu CA, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Hepatology. 2012 Sep 3. doi: 10.1002/hep.26041. [Epub ahead of print]


  229. Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy
    Ko SY, Choe WH, Kwon SY, Kim JH, Seo JW, Kim KH, Lee CH. Scand J Gastroenterol. 2012 Aug 31. [Epub ahead of print]


  230. Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients
    Lai HW, Chang CC, Chen TH, Tsai MC, Chen TY, Lin CC. J Formos Med Assoc. 2012 Aug;111(8):439-44. Epub 2012 Apr 30.


  231. Association of response to hepatitis B vaccination and survival in dialysis patients
    Lin SY, Liu JH, Wang SM, Wang IK, Tsai CA, Liu YL, Lin HH, Chang CC, Huang CC. BMC Nephrol. 2012 Aug 30;13(1):97. [Epub ahead of print]


  232. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B
    Buti M, Homs M. Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):413-21.


  233. Chronic HBV infection outside treatment guidelines: is treatment needed?
    Evans AA, London WT, Gish RG, Cohen C, Block TM. Antivir Ther. 2012 Aug 20. doi: 10.3851/IMP2325. [Epub ahead of print]


  234. Unexpected distribution of Hepatitis B genotypes in patients with kidney disease: Comparison with immunocompetent subjects
    Souza LO, Perez RM, Carvalho-Filho RJ, Matos CA, Moutinho RS, Silva IS, Medina-Pestana JO, Silva AE, Ferraz ML. J Med Virol. 2012 Oct;84(10):1548-52. doi: 10.1002/jmv.23357.


  235. Subgenotype reclassification of genotype B hepatitis B virus
    Shi W, Zhu C, Zheng W, Carr MJ, Higgins DG, Zhang Z. Abstract BMC Gastroenterol. 2012 Aug 27;12(1):116. [Epub ahead of print]


  236. Does genotype predict response to treatment in children infected with hepatitis B perinatally?
    Boxall E, Sira J, Kaskar S, Workman J, Kelly D. J Med Virol. 2012 Oct;84(10):1535-40. doi: 10.1002/jmv.23308.


  237. Increased Risk of Acute Hepatitis B among Adults with Diagnosed Diabetes MellitusIncreased Risk of Acute Hepatitis B among Adults with Diagnosed Diabetes Mellitus
    Reilly ML, Schillie SF, Smith E, Poissant T, Vonderwahl CW, Gerard K, Baumgartner J, Mercedes L, Sweet K, Muleta D, Zaccaro DJ, Klevens RM, Murphy TV. J Diabetes Sci Technol. 2012 Jul 1;6(4):858-66.


  238. Hepatitis B virus management to prevent reactivation after chemotherapy: a review
    Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R. Support Care Cancer. 2012 Aug 30. [Epub ahead of print]


  239. Cost-effectiveness analysis of preventing mother-to-child transmission of hepatitis B by injecting hepatitis B immune globulin
    Guo Y, Zhang W, Zhang Y, Lin X, Zhang B, Chen C, Du Y. Eur J Gastroenterol Hepatol. 2012 Aug 23. [Epub ahead of print]


  240. High Hepatitis B Surface Antigen Levels Predict Insignificant Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis B
    Seto WK, Wong DK, Fung J, Ip PP, Yuen JC, Hung IF, Lai CL, Yuen MF. PLoS One. 2012;7(8):e43087. Epub 2012 Aug 20.


  241. Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus
    Shima T, Uto H, Ueki K, Takamura T, Kohgo Y, Kawata S, Yasui K, Park H, Nakamura N, Nakatou T, Tanaka N, Umemura A, Mizuno M, Tanaka J, Okanoue T. J Gastroenterol. 2012 Aug 22. [Epub ahead of print]


  242. Limited infection with occult hepatitis B virus in drug users in the USA
    Blackard JT, Martin CM, Sengupta S, Forrester J. Hepatol Res. 2012 Jul 9. doi: 10.1111/j.1872-034X.2012.01072.x. [Epub ahead of print]


  243. Identification of a liver cirrhosis signature in plasma for predicting hepatocellular carcinoma risk in a population-based cohort of hepatitis B carriers
    Liu CC, Wang YH, Chuang EY, Tsai MH, Chuang YH, Lin CL, Liu CJ, Hsiao BY, Lin SM, Liu LY, Yu MW. Mol Carcinog. 2012 Aug 21. doi: 10.1002/mc.21952. [Epub ahead of print]


  244. Future Prevention and Treatment of Chronic Hepatitis B Infection
    Seto WK, Fung J, Yuen MF, Lai CL. J Clin Gastroenterol. 2012 Aug 23. [Epub ahead of print]


  245. Hepatitis in the elderly: still a scourge
    Wick JY. Consult Pharm. 2012 Jul;27(7):472-81.


  246. Ammonium metabolism in humans
    Adeva MM, Souto G, Blanco N, Donapetry C. Metabolism. 2012 Aug 23. [Epub ahead of print]


  247. Serum markers for predicting significant necroinflammatory activity in patients with chronic hepatitis B
    Cho HJ, Kim SS, Ahn SJ, Bae CB, Kim HG, Kim YJ, Lee SK, Song GW, Kim DJ, Hwang SG, Yang JM, Kim YB, Park YN, Cho SW, Cheong JY. Clin Biochem. 2012 Aug 3. [Epub ahead of print]


  248. Impact of maternal carrier status on immunologic markers for protection after hepatitis B vaccination in infancy: A meta-analysis
    Schönberger K, Riedel C, Rückinger S, Mansmann U, Jilg W, von Kries R. Vaccine. 2012 Aug 8. [Epub ahead of print]


  249. Comparison of four prognostic models and a new Logistic regression model to predict short-term prognosis of acute-on-chronic hepatitis B liver failure
    He WP, Hu JH, Zhao J, Tong JJ, Ding JB, Lin F, Wang HF. Chin Med J (Engl). 2012 Jul;125(13):2272-8.


  250. Clinical prediction of failure of lamivudine prophylaxis for patients with hepatitis B infection undergoing cytotoxic chemotherapy for malignancy
    Kim IK, Kim BG, Kim W, Kim D, Kim YJ, Yoon JH, Lee HS. Antimicrob Agents Chemother. 2012 Aug 13. [Epub ahead of print]


  251. Posthepatectomy HBV Reactivation in Hepatitis B-Related Hepatocellular Carcinoma Influences Postoperative Survival in Patients With Preoperative Low HBV-DNA Levels
    Posthepatectomy HBV Reactivation in Hepatitis B-Related Hepatocellular Carcinoma Influences Postoperative Survival in Patients With Preoperative Low HBV-DNA Levels


  252. A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virologic response to lamivudine
    Heo J, Park JY, Lee HJ, Tak WY, Um SH, Kim DY, Yoon KT, Park SY, Seo YS, Han KH, Cho M, Ahn SH. Antivir Ther. 2012 Aug 8. doi: 10.3851/IMP2277. [Epub ahead of print]


  253. Update on tenofovir toxicity in the kidney
    Hall AM. Pediatr Nephrol. 2012 Aug 10. [Epub ahead of print]


  254. Tattooing and risk of hepatitis B: a systematic review and meta-analysis
    Jafari S, Buxton JA, Afshar K, Copes R, Baharlou S. Can J Public Health. 2012 May-Jun;103(3):207-12.


  255. Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy
    Peng JW, Lin GN, Xiao JJ, Jiang XM. Asia Pac J Clin Oncol. 2012 May 15. doi: 10.1111/j.1743-7563.2012.01534.x. [Epub ahead of print]


  256. Hepatitis B reactivation in cancer patients: role of prechemotherapy screening and antiviral prophylaxis
    Kawsar HI, Shahnewaz J, Gopalakrishna KV, Spiro TP, Daw HA. Clin Adv Hematol Oncol. 2012 Jun;10(6):370-8.


  257. Management of chemotherapy-induced hepatitis B virus reactivation
    Huang YH, Lin HC, Lee SD. J Chin Med Assoc. 2012 Aug;75(8):359-62. Epub 2012 Jul 21.


  258. A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier
    Bae JH, Sohn JH, Lee HS, Park HS, Hyun YS, Kim TY, Eun CS, Jeon YC, Han DS. Clin Mol Hepatol. 2012 Jun;18(2):225-8. Epub 2012 Jun 26.


  259. PS2-03: Chronic Hepatitis B Testing in US-born and Foreign-born Asia Pacific Islanders of Kaiser Permanente, Hawai'i
    Vijayadeva V, Lu M, Nakasato C, Gordon S, Rupp L, Henkle E. Clin Med Res. 2012 Aug;10(3):172.


  260. Value of Abdominal Susceptibility-weighted Magnetic Resonance Imaging for Quantitative Assessment of Hepatic Iron Deposition in Patients with Chronic Hepatitis B: Comparison with Serum Iron Markers
    Lv W, Yan F, Zeng M, Zhang J, Yuan Y, Ma J. J Int Med Res. 2012;40(3):1005-15.


  261. Effects of hepatitis B e-antigen on recurrence of hepatitis B-related hepatocellular carcinoma after curative resection: A meta-analysis
    Qu LS, Zhu J, Chen H, Jin F, Ni RZ, Lu CH. Hepatol Res. 2012 Jul 23. doi: 10.1111/j.1872-034X.2012.01079.x. [Epub ahead of print]


  262. Clinical and Virological Characteristics Post HBsAg Seroclearance in Hepatitis B Virus Carriers With Hepatic Steatosis Versus Those Without
    Chu CM, Lin DY, Liaw YF. Dig Dis Sci. 2012 Aug 18. [Epub ahead of print]


  263. Diagnosis and personalized management of hepatitis B including significance of genotypes
    Wong VW, Sung JJ. Curr Opin Infect Dis. 2012 Aug 16. [Epub ahead of print]


  264. CB3-02: Demographic Differences Between US-born and Foreign-born Asia Pacific Islanders Among the Hepatitis B Patients of Kaiser Permanente, Hawai'i
    Vijayadeva V, Nakasato C, Gordon S, Rupp L, Lu M, Henkle E, Boscarino J. Clin Med Res. 2012 Aug;10(3):172-3.


  265. Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection
    Chung WG, Kim HJ, Choe YG, Seok HS, Chon CW, Cho YK, Kim BI, Koh YY. Clin Mol Hepatol. 2012 Jun;18(2):195-202. Epub 2012 Jun 26.


  266. Fatal hepatitis B reactivation treated with entecavir in an isolated anti-HBs positive lymphoma patient: A case report and literature review
    Ferreira R, Carvalheiro J, Torres J, Fernandes A, Giestas S, Mendes S, Agostinho C, Campos MJ. Saudi J Gastroenterol. 2012 Jul;18(4):277-81.


  267. Updated thresholds for serum alanine aminotransferase level in a large-scale population study composed of 34 346 subjects
    Wu WC, Wu CY, Wang YJ, Hung HH, Yang HI, Kao WY, Su CW, Wu JC, Chan WL, Lin HC, Lee FY, Lee SD. Aliment Pharmacol Ther. 2012 Jul 23. doi: 10.1111/j.1365-2036.2012.05224.x. [Epub ahead of print]


  268. Randomised study comparing 48 and 96 weeks peginterferon ?-2a therapy in genotype D HBeAg-negative chronic hepatitis B
    Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, Boninsegna S, Farci P, Fargion S, Giuberti T, Iannacone C, Regep L, Massetto B, Facchetti F, Colombo M; on behalf of the PegBeLiver Study Group. Gut. 2012 Aug 2. [Epub ahead of print]


  269. Sleep and antibody response to hepatitis B vaccination
    Prather AA, Hall M, Fury JM, Ross DC, Muldoon MF, Cohen S, Marsland AL. Sleep. 2012 Aug 1;35(8):1063-9.


  270. Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B
    Kim SS, Lee D, Lee MH, Cheong JY, Cho SW. Hepatol Res. 2012 Jun 27. doi: 10.1111/j.1872-034X.2012.01065.x. [Epub ahead of print]


  271. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma
    Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, McKeegan EM, Dowell B, Pedersen M, Qin Q, Qian J, Scappaticci FA, Ricker JL, Carlson DM, Yong WP. Cancer. 2012 Jul 25. doi: 10.1002/cncr.27758. [Epub ahead of print]Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, McKeegan EM, Dowell B, Pedersen M, Qin Q, Qian J, Scappaticci FA, Ricker JL, Carlson DM, Yong WP. Cancer. 2012 Jul 25. doi: 10.1002/cncr.27758. [Epub ahead of print]


  272. Serological prevalence of hepatitis B virus and hepatitis C virus infection in the elderly population: Polish nationwide survey - PolSenior
    Hartleb M, Gutkowski K, Zejda JE, Chudek J, Wi?cek A. Eur J Gastroenterol Hepatol. 2012 Aug 1. [Epub ahead of print]


  273. The role of innate immunity in HBV infection
    Han Q, Zhang C, Zhang J, Tian Z. Semin Immunopathol. 2012 Jul 20. [Epub ahead of print]


  274. Theoretically Informed Correlates of Hepatitis B Knowledge among Four Asian Groups: The Health Behavior Framework
    Maxwell AE, Stewart SL, Glenn BA, Wong WK, Yasui Y, Chang LC, Taylor VM, Nguyen TT, Chen MS, Bastani R. Asian Pac J Cancer Prev. 2012;13(4):1687-92.


  275. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy
    Lai CL, Yuen MF. Hepatology. 2012 Jul 13. doi: 10.1002/hep.25937. [Epub ahead of print]


  276. Comparison of LecT-Hepa and FibroScan for assessment of liver fibrosis in hepatitis B virus infected patients with different ALT levels
    Du D, Zhu X, Kuno A, Matsuda A, Tsuruno C, Yu D, Zhang Y, Ikehara Y, Tanaka Y, Zhang X, Narimatsu H. Clin Chim Acta. 2012 Jul 12. [Epub ahead of print]


  277. Health state utilities and quality of life in patients with hepatitis B
    Woo G, Tomlinson G, Yim C, Lilly L, Therapondos G, Wong DK, Ungar WJ, Einarson TR, Sherman M, Heathcote JE, Krahn M. Can J Gastroenterol. 2012 Jul;26(7):445-51.


  278. Restored Function of HBV-Specific T Cells after Long-Term Effective Therapy with Nucleos(t)ide Analogues
    Boni C, Laccabue D, Lampertico P, Giuberti T, Viganò M, Schivazappa S, Alfieri A, Pesci M, Gaeta GB, Brancaccio G, Colombo M, Missale G, Ferrari C. Gastroenterology. 2012 Jul 12. [Epub ahead of print]


  279. Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis
    Zhou Y, Zhao Y, Li B, Huang J, Wu L, Xu D, Yang J, He J. BMC Cancer. 2012 Jul 16;12(1):289. [Epub ahead of print]


  280. Updated CDC Recommendations for the Management of Hepatitis B Virus-Infected Health-Care Providers and Students
    Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. MMWR Recomm Rep. 2012 Jul 6;61(RR-3):1-12.


  281. Assessing Long-Term Treatment Efficacy in Chronic Hepatitis B and C: Between Evidence and Common Sense
    Aghemo A, Lampertico P, Colombo M. J Hepatol. 2012 Jun 27. [Epub ahead of print]


  282. A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women
    Sun KX, Li J, Zhu FC, Liu JX, Li RC, Zhai XJ, Li YP, Chang ZJ, Nie JJ, Zhuang H. Vaccine. 2012 Jun 26. [Epub ahead of print]


  283. Real-time Elastography for Diagnosis of Liver Fibrosis in Chronic Hepatitis B
    Xie L, Chen X, Guo Q, Dong Y, Guang Y, Zhang X. J Ultrasound Med. 2012 Jul;31(7):1053-60.


  284. Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir
    Chen EQ, Zhou TY, Bai L, Wang JR, Yan LB, Liang LB, Tang H. Antivir Ther. 2012 Jun 22. doi: 10.3851/IMP2190. [Epub ahead of print]


  285. Rescue Therapy for Lamivudine-resistant Chronic Hepatitis B: Adefovir Monotherapy, Adefovir Plus Lamivudine or Entecavir Combination Therapy
    Ha M, Zhang G, Diao S, Lin M, Wu J, Sun L, She H, Shen L, Huang C, Shen W, Huang Z. Intern Med. 2012;51(12):1509-15. Epub 2012 Jun 15.


  286. Antiviral therapy: old and current issues
    Antonelli G, Turriziani O. Int J Antimicrob Agents. 2012 Jun 21. [Epub ahead of print]


  287. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management
    Abramson A, Menter A, Perrillo R. J Am Acad Dermatol. 2012 Jun 21. [Epub ahead of print]


  288. Diverse roles of hepatitis B virus in liver cancer
    Fallot G, Neuveut C, Buendia MA. Curr Opin Virol. 2012 Jun 19. [Epub ahead of print]


  289. Exploring hepatitis B: a neglected disease
    Loo NM, Pryce DJ. Minn Med. 2012 May;95(5):37-40.


  290. Hepatitis B Virus Screening Before Chemotherapy for Lymphoma: A Cost-Effectiveness Analysis
    Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, Chan KK, Feld JJ. J Clin Oncol. 2012 Jun 18. [Epub ahead of print]


  291. Optimal Management of the Hepatitis B Patient Who Desires Pregnancy or Is Pregnant
    Bzowej NH. Curr Hepat Rep. 2012 Jun;11(2):82-89. Epub 2012 May 26.


  292. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy
    Oketani M, Ido A, Uto H, Tsubouchi H. Hepatol Res. 2012 Jul;42(7):627-36. doi: 10.1111/j.1872-034X.2012.00998.x.


  293. Prevention and Management of Drug Resistant HBV Infections
    Wang C, Fan R, Sun J, Hou J. J Gastroenterol Hepatol. 2012 Jun 13. doi: 10.1111/j.1440-1746.2012.07198.x. [Epub ahead of print]


  294. Evaluation of elevated alanine aminotransferase and hepatitis B virus DNA in healthy seronegative blood donors
    Ali N, Moiz B, Moatter T. BMC Res Notes. 2012 Jun 7;5(1):272. [Epub ahead of print]


  295. Precore mutation of hepatitis B virus may contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis
    Liao Y, Hu X, Chen J, Cai B, Tang J, Ying B, Wang H, Wang L. PLoS One. 2012;7(6):e38394. Epub 2012 Jun 1.


  296. Serologic Testing for Protection against Hepatitis B Virus Infection among Students at a Health Sciences University in the United States
    Spradling PR, Williams RE, Xing J, Soyemi K, Towers J. Infect Control Hosp Epidemiol. 2012 Jul;33(7):732-6. Epub 2012 May 22.


  297. Relationship between HLA-DR gene polymorphisms and outcomes of hepatitis B viral infections: A meta-analysis
    Yan ZH, Fan Y, Wang XH, Mao Q, Deng GH, Wang YM. World J Gastroenterol. 2012 Jun 28;18(24):3119-28.


  298. Optimal time for restoring the reliability of liver stiffness measurement in patients with chronic hepatitis B experiencing acute exacerbation
    Park H, Kim SU, Kim D, Kim do Y, Ahn SH, Han KH, Chon CY, Park JY. J Clin Gastroenterol. 2012 Aug;46(7):602-7.


  299. HBsAg variants: Diagnostic-escape and diagnostic dilemma
    Alavian SM, Carman WF, Jazayeri SM. J Clin Virol. 2012 Jul 10. [Epub ahead of print]


  300. Hepatitis B Virus and Human Immunodeficiency Virus Drugs in Pregnancy: Findings from the Antiretroviral Pregnancy Registry
    Brown RS, Verna EC, Pereira MR, Tilson HH, Aguilar C, Leu CS, Buti M, Fagan EA. J Hepatol. 2012 Jul 2. [Epub ahead of print]


  301. Adherence, Persistence, Healthcare Utilization, and Cost Benefits of Guideline-Recommended Hepatitis B Pharmacotherapy
    Han SH, Jing W, Mena E, Li M, Pinsky B, Tang H, Hebden T, Juday T. J Med Econ. 2012 Jul 10. [Epub ahead of print]


  302. Healthcare workers' perceptions of occupational exposure to blood-borne viruses and reporting barriers: a questionnaire-based study
    Winchester SA, Tomkins S, Cliffe S, Batty L, Ncube F, Zuckerman M. J Hosp Infect. 2012 Jul 9. [Epub ahead of print]


  303. Minimization of HBV Infection by A 25-Year Universal Vaccination Program
    Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. J Hepatol. 2012 Jun 2. [Epub ahead of print]


  304. A community-based participatory approach to a hepatitis B intervention for Korean Americans
    Ma GX, Gao W, Tan Y, Chae WG, Rhee J. Prog Community Health Partnersh. 2012 Spring;6(1):7-16.


  305. Clinical usefulness of measuring red blood cell distribution width in patients with hepatitis B
    Lou Y, Wang M, Mao W. PLoS One. 2012;7(5):e37644. Epub 2012 May 23.


  306. Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon ?-2a: progressive decrease in hepatitis B surface antigen in responders
    Rijckborst V, Ferenci P, Akdogan M, Pinarbasi B, Ter Borg MJ, Simon K, Flisiak R, Akarca US, Raptopoulou-Gigi M, Verhey E, van Vuuren AJ, Boucher CA, Hansen BE, Janssen HL; for the PARC Study Group. Eur J Gastroenterol Hepatol. 2012 Jun 3. [Epub ahead of print]


  307. Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients with Chronic Hepatitis B Who Stop Long-Term Treatment with Adefovir
    Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Gastroenterology. 2012 May 31. [Epub ahead of print]


  308. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients
    Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H. J Hepatol. 2012 May 30. [Epub ahead of print]


  309. Chronic hepatitis B in children and adolescents
    Paganelli M, Stephenne X, Sokal EM. J Hepatol. 2012 May 22. [Epub ahead of print]


  310. Rewards program is the best and they have the most direct flights out of Newark. Rapid Point-of-Care First-Line Screening Tests for Hepatitis B Infection: A Meta-Analysis of Diagnostic Accuracy (1980-2010)
    Shivkumar S, Peeling R, Jafari Y, Joseph L, Pai NP. Am J Gastroenterol. 2012 May 29. doi: 10.1038/ajg.2012.141. [Epub ahead of print]


  311. High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG
    Shahmoradi S, Yahyapour Y, Mahmoodi M, Alavian SM, Fazeli Z, Jazayeri SM. J Hepatol. 2012 May 19. [Epub ahead of print]


  312. Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation
    Liu CY, Chandrasekar PH, Masood A, Schiffer CA. J Oncol Pharm Pract. 2012 May 25. [Epub ahead of print]


  313. Efficacy of Entecavir with or without Tenofovir Disoproxil Fumarate for Nucleos(t)ide-Naïve Patients with Chronic Hepatitis B
    Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D, Lovegren M, Cohen D, Llamoso C. Gastroenterology. 2012 May 26. [Epub ahead of print]


  314. Hepatitis B vaccine: prophylactic, therapeutic, and diagnostic dilemma
    Alavian SM, Miri SM, Jazayeri SM. Minerva Gastroenterol Dietol. 2012 Jun;58(2):167-78.


  315. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice
    Pol S, Lampertico P. J Viral Hepat. 2012 Jun;19(6):377-86. doi: 10.1111/j.1365-2893.2012.01602.x. Epub 2012 Mar 28.


  316. Factors influencing inadequate or suboptimal response to adefovir with or without genotypic resistance
    Zhou X, Kuang X, Fan K, Zhang C, Deng G, Wang H, Wang Y. J Med Virol. 2012 Jul;84(7):1030-6. doi: 10.1002/jmv.23270.


  317. The prevalence of hepatitis B and C viral infections among pregnant women
    Ugbebor O, Aigbirior M, Osazuwa F, Enabudoso E, Zabayo O. N Am J Med Sci. 2011 May;3(5):238-41.


  318. Improving Adult Immunization Practices Using a Team Approach in the Primary Care Setting
    Gannon M, Qaseem A, Snooks Q, Snow V. Am J Public Health. 2012 May 17. [Epub ahead of print]


  319. Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B
    Toyama T, Ishida H, Ishibashi H, Yatsuhashi H, Nakamuta M, Shimada M, Ohta H, Satoh T, Kato M, Hijioka T, Takano H, Komeda T, Yagura M, Mano H, Watanabe Y, Kobayashi M, Mita E. Hepatol Res. 2012 Apr 19. doi: 10.1111/j.1872-034X.2012.01038.x. [Epub ahead of print]


  320. Genotype impact on long-term virological outcome of chronic hepatitis B virus infection
    Malmström S, Eilard A, Larsson SB, Hannoun C, Norkrans G, Lindh M. J Clin Virol. 2012 May 17. [Epub ahead of print]


  321. Investigation of viral hepatitis infections possibly associated with health-care delivery - new york city, 2008-2011
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2012 May 18;61:333-8.


  322. Improving adult immunization practices using a team approach in the primary care setting
    Gannon M, Qaseem A, Snooks Q, Snow V. Am J Public Health. 2012 Jul;102(7):e46-52. Epub 2012 May 17.


  323. Multiple outbreaks of hepatitis B virus infection related to assisted monitoring of blood glucose among residents of assisted living facilities - virginia, 2009-2011
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2012 May 18;61:339-43.


  324. Do hepatitis B virus and hepatitis C virus co-infections increase hepatocellular carcinoma occurrence through synergistically modulating lipogenic gene expression?
    Wu Q, Liu Q. Hepatol Res. 2012 Mar 2. doi: 10.1111/j.1872-034X.2012.00994.x. [Epub ahead of print]


  325. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years
    Wong GL, Wong VW, Chan HY, Tse PC, Wong J, Chim AM, Yiu KK, Chu SH, Chan HL. Aliment Pharmacol Ther. 2012 Apr 16. doi: 10.1111/j.1365-2036.2012.05098.x. [Epub ahead of print]


  326. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis
    Zoutendijk R, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, Deterding K, Hofmann WP, Petersen J, Fasano M, Buti M, Berg T, Hansen BE, Sonneveld MJ, Wedemeyer H, Janssen HL; for the VIRGIL Surveillance Study Group. Gut. 2012 Apr 5. [Epub ahead of print]


  327. Is there an association between the measurement of qualitative HBsAg and virologic response in chronic HBV infection?
    Altinbas A, Aktas B, Basar O, Yüksel O, Ekiz F, Yilmaz B, Coban S. Ann Hepatol. 2012 May;11(3):320-5.


  328. Relationship between interleukin 18 polymorphisms and susceptibility to chronic hepatitis B virus infection
    Li N, Gao YF, Zhang TC, Chen P, Li X, Su F. World J Hepatol. 2012 Mar 27;4(3):105-9.


  329. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B
    Gara N, Zhao X, Collins MT, Chong WH, Kleiner DE, Jake Liang T, Ghany MG, Hoofnagle JH. Aliment Pharmacol Ther. 2012 Apr 16. doi: 10.1111/j.1365-2036.2012.05093.x. [Epub ahead of print]


  330. Similar Risk of Renal Events Among Patients Treated with Tenofovir or Entecavir for Chronic Hepatitis B
    Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Clin Gastroenterol Hepatol. 2012 Apr 13. [Epub ahead of print]


  331. Natural history of chronic hepatitis B: what exactly has REVEAL Revealed?
    Iloeje UH, Yang HI, Chen CJ. Liver Int. 2012 Apr 17. doi: 10.1111/j.1478-3231.2012.02805.x. [Epub ahead of print]


  332. New insight in the pathobiology of hepatitis B virus infection
    Dandri M, Locarnini S. Gut. 2012 May;61 Suppl 1:i6-i17.


  333. Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection
    Falade-Nwulia O, Seaberg EC, Rinaldo CR, Badri S, Witt M, Thio CL. Clin Infect Dis. 2012 Apr 20. [Epub ahead of print]


  334. Management of HBV- and HCV-induced end stage liver disease
    Mutimer DJ, Lok A. Gut. 2012 May;61 Suppl 1:i59-i67.


  335. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: Meta-analysis
    Naing C, Mak JW, Ahmed SI, Maung M. World J Gastroenterol. 2012 Apr 14;18(14):1642-51.


  336. Impact of comorbidities on the severity of chronic hepatitis B at presentation
    Sagnelli E, Stroffolini T, Mele A, Imparato M, Sagnelli C, Coppola N, Almasio PL. World J Gastroenterol. 2012 Apr 14;18(14):1616-21.


  337. Hepatitis B: treatment to prevent perinatal transmission
    Tran TT. Clin Obstet Gynecol. 2012 Jun;55(2):541-9.


  338. New virologic tools for management of chronic hepatitis B and C
    Chevaliez S, Rodriguez C, Pawlotsky JM. Gastroenterology. 2012 May;142(6):1303-1313.e1.


  339. Effectiveness of hepatitis B treatment in clinical practice
    Scaglione SJ, Lok AS. Gastroenterology. 2012 May;142(6):1360-1368.e1.


  340. Association between obesity, hypertriglyceridemia and low hepatitis B viral load
    Chiang CH, Yang HI, Jen CL, Lu SN, Wang LY, You SL, Su J, Iloeje UH, Chen CJ. Int J Obes (Lond). 2012 Apr 24. doi: 10.1038/ijo.2012.63. [Epub ahead of print]


  341. Prospective Validation of FibroTest in Comparison with Liver Stiffness for Predicting Liver Fibrosis in Asian Subjects with Chronic Hepatitis B
    Kim BK, Kim SU, Kim HS, Park JY, Ahn SH, Chon CY, Cho IR, Joh DH, Park YN, Han KH, Kim do Y. PLoS One. 2012;7(4):e35825. Epub 2012 Apr 20.


  342. Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma
    Chen H, Sun LY, Zheng HQ, Zhang QF, Jin XM. Pathology. 2012 Apr 23. [Epub ahead of print]


  343. Modest Alcohol Consumption has an Inverse Association with Liver Fat Content
    Gunji T, Sato H, Iijima K, Fujibayashi K, Okumura M, Sasabe N, Matsuhashi N. Hepatogastroenterology. 2012 Apr 25;59(120). doi: 10.5754/hge12175. [Epub ahead of print]


  344. Association between Hepatic Steatosis and Entecavir Treatment Failure in Chinese Patients with Chronic Hepatitis B
    Jin X, Chen YP, Yang YD, Li YM, Zheng L, Xu CQ. PLoS One. 2012;7(3):e34198. Epub 2012 Mar 30.


  345. High Rates of Viral Suppression After Long-Term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B
    Pan CQ, Tong M, Kowdley KV, Hu KQ, Chang TT, Lai CL, Yoon SK, Lee SS, Cohen D, Tang H, Tsai N. Clin Gastroenterol Hepatol. 2012 Apr 1. [Epub ahead of print]


  346. Different models in predicting the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure
    Yang WB, Chen EQ, Bi HX, Bai L, Chen XB, Feng P, Tang H. Ann Hepatol. 2012 May;11(3):311-9.


  347. Increased levels of Arginase in patients with acute hepatitis B suppress antiviral T cells
    Sandalova E, Laccabue D, Boni C, Watanabe T, Tan A, Zong HZ, Ferrari C, Bertoletti A. Gastroenterology. 2012 Apr 1. [Epub ahead of print]


  348. Saliva as a tool in the detection of hepatitis B surface antigen in patients
    Arora G, Sheikh S, Pallagatti S, Singh B, Singh VA, Singh R. Compend Contin Educ Dent. 2012 Mar;33(3):174-6, 178; quiz 180, 182.


  349. Hepatitis B serology
    Towell V, Cowie B. Aust Fam Physician. 2012 Apr;41(4):212-4.


  350. IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B
    Lampertico P, Viganò M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, Soffredini R, Abrignani S, De Francesco R, Colombo M. Hepatology. 2012 Apr 2. doi: 10.1002/hep.25749. [Epub ahead of print]


  351. Telomere length in circulating serum DNA as a novel non-invasive biomarker for cirrhosis: a nested case-control analysis
    Wan S, Hann HW, Myers RE, Fu X, Hann RS, Kim SH, Tang H, Xing J, Yang H. Liver Int. 2012 Apr 4. doi: 10.1111/j.1478-3231.2012.02801.x. [Epub ahead of print]


  352. Patients with hematological malignancies and serological signs of prior resolved hepatitis B
    Marignani M, Gigante E, Begini P, Marzano A, di Fonzo M, Deli I, Gallina S, Cox MC, Delle Fave G. World J Gastrointest Oncol. 2012 Mar 15;4(3):37-45.


  353. Circulating Hepatitis B Surface Antigen Particles Carry Hepatocellular microRNAs
    Novellino L, Rossi RL, Bonino F, Cavallone D, Abrignani S, Pagani M, Brunetto MR. PLoS One. 2012;7(3):e31952. Epub 2012 Mar 28.


  354. Baseline hepatitis B vaccination coverage among persons with diabetes before implementing a U.S. recommendation for vaccination
    Byrd KK, Lu PJ, Murphy TV. Vaccine. 2012 Mar 31. [Epub ahead of print]


  355. Improved Efficacy by Individualized Combination Therapy with Peg IFN-a 2a and ADV in HBeAg Positive Chronic Hepatitis B Patients
    Wang YD, Zhao CY, Wang W, Shen C, Lu HZ, Zhang L, Yu WY, Zhou JY, Yan WZ. Hepatogastroenterology. 2012 Mar 20;59(115). doi: 10.5754/hge12183. [Epub ahead of print]


  356. Transient elastography and simple blood markers in diagnosis of oesophageal varices for compensated patients with hepatitis B virus-related cirrhosis
    Wang JH, Chuah SK, Lu SN, Hung CH, Chen CH, Kee KM, Chang KC, Tai WC, Hu TH. J Gastroenterol Hepatol. 2012 Mar 20. doi: 10.1111/j.1440-1746.2012.07132.x. [Epub ahead of print]


  357. High hepatitis B virus infection in B-cell lymphoma tissue and its potential clinical relevance
    Wang F, Yuan S, Teng KY, Garcia-Prieto C, Luo HY, Zeng MS, Rao HL, Xia Y, Jiang WQ, Huang HQ, Xia ZJ, Sun XF, Xu RH. Eur J Cancer Prev. 2012 May;21(3):261-7.


  358. New advances in chronic hepatitis B
    Tujios SR, Lee WM. Curr Opin Gastroenterol. 2012 Mar 23. [Epub ahead of print]


  359. Undertreatment of Asian Chronic Hepatitis B Patients on the Basis of Standard Guidelines: A Community-Based Study
    Zhang S, Ristau JT, Trinh HN, Garcia RT, Nguyen HA, Nguyen MH. Dig Dis Sci. 2012 Mar 31. [Epub ahead of print]


  360. Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B
    Ghany MG, Feld JJ, Zhao X, Heller T, Doo E, Rotman Y, Nagabhyru P, Koh C, Kleiner DE, Wright EC, Liang TJ, Hoofnagle JH. Aliment Pharmacol Ther. 2012 Mar 26. doi: 10.1111/j.1365-2036.2012.05059.x. [Epub ahead of print]


  361. Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir
    Son CY, Ryu HJ, Lee JM, Ahn SH, Kim DY, Lee MH, Han KH, Chon CY, Park JY. Liver Int. 2012 Mar 27. doi: 10.1111/j.1478-3231.2012.02793.x. [Epub ahead of print]


  362. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review
    Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. J Hepatol. 2012 Mar 23. [Epub ahead of print]


  363. Hepatitis B vaccination of susceptible elderly residents of long term care facilities during a hepatitis B outbreak
    Williams RE, Sena AC, Moorman AC, Moore ZS, Sharapov UM, Drobenuic J, Hu DJ, Wood HW, Xing J, Spradling PR. Vaccine. 2012 Mar 12. [Epub ahead of print]


  364. Evaluation of adherence to oral antiviral hepatitis B treatment using structured questionnaires
    Giang L, Selinger CP, Lee AU. World J Hepatol. 2012 Feb 27;4(2):43-9.


  365. A large case-control study on the predictability of hepatitis B surface antigen (HBsAg) levels three years before HBsAg seroclearance
    Seto WK, Wong DK, Fung J, Hung IF, Fong DY, Yuen JC, Tong T, Lai CL, Yuen MF. Hepatology. 2012 Mar 15. doi: 10.1002/hep.25718. [Epub ahead of print]


  366. Prevention of de novo hepatitis B with adefovir dipivoxil (ADV) in recipients of liver grafts from hepatitis B core antibody positive (HBcAb+) donors
    Chang MS, Olsen SK, Pichardo EM, Heese S, Stiles JB, Abdelmessih R, Verna EC, Guarrera JV, Emond JC, Brown RS. Liver Transpl. 2012 Mar 16. doi: 10.1002/lt.23429. [Epub ahead of print]


  367. Model for End-stage Liver Disease and Model for End-stage Liver Disease-Na Scores Predict Both Before-Listing and Wait-List Mortality
    Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Nojiri K, Aoki T, Sakamoto Y, Hasegawa K, Koike K, Kokudo N. Transplant Proc. 2012 Mar;44(2):389-92.


  368. The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma - a review
    Marcucci F, Spada E, Mele A, Caserta CA, Pulsoni A. Am J Blood Res. 2012;2(1):18-28. Epub 2012 Jan 1.


  369. Hepatitis B virus regulatory HBx protein binding to DDB1 is required but is not sufficient for maximal HBV replication
    Hodgson AA, Hyser JM, Keasler VV, Cang Y, Slagle BL. Virology. 2012 Feb 16. [Epub ahead of print]


  370. Role of hyaluronic acid and laminin as serum markers for predicting significant fibrosis in patients with chronic hepatitis B
    Li F, Zhu CL, Zhang H, Huang H, Wei Q, Zhu X, Cheng XY. Braz J Infect Dis. 2012 Feb;16(1):9-14.


  371. Hepatitis B Infection in the Asian and Latino Communities of Alameda County, California
    Hur K, Wong M, Lee J, Lee J, Juon HS. J Community Health. 2012 Feb 24. [Epub ahead of print]


  372. Hepatitis B virus variant with the a194t substitution within reverse transcriptase before and under adefovir and tenofovir therapy
    Dupouey J, Gerolami R, Solas C, Colson P. Clin Res Hepatol Gastroenterol. 2012 Feb 17. [Epub ahead of print]


  373. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNF? agents: A retrospective analysis of 49 cases
    Ryu HH, Lee EY, Shin K, Choi IA, Lee YJ, Yoo B, Park MC, Park YB, Bae SC, Yoo WH, Kim SI, Lee EB, Song YW. Clin Rheumatol. 2012 Feb 17. [Epub ahead of print]


  374. Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation
    Todd Stravitz R, Shiffman ML, Kimmel M, Puri P, Luketic VA, Sterling RK, Sanyal AJ, Cotterell AH, Posner MP, Fisher RA. Liver Int. 2012 Feb 21. doi: 10.1111/j.1478-3231.2012.02770.x. [Epub ahead of print]


  375. Kinetics of HBs and HBe antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-HBV infected patients
    Maylin S, Boyd A, Lavocat F, Gozlan J, Lascoux-Combe C, Miailhes P, Lassel L, Delaugerre C, Girard PM, Zoulim F, Lacombe K. AIDS. 2012 Feb 13. [Epub ahead of print]


  376. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis
    Jin W, Lin Z, Xin Y, Jiang X, Dong Q, Xuan S. BMC Gastroenterol. 2012 Feb 14;12(1):14. [Epub ahead of print]


  377. Pivotal roles of the interleukin-23/T helper 17 cell axis in hepatitis B
    Huang Z, van Velkinburgh JC, Ni B, Wu Y. Liver Int. 2012 Feb 19. doi: 10.1111/j.1478-3231.2012.02764.x. [Epub ahead of print]


  378. High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients with Low HBV Load
    Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Gastroenterology. 2012 Feb 11. [Epub ahead of print]


  379. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients
    Idilman R, Cinar K, Seven G, Bozkus Y, Elhan A, Bozdayi M, Yurdaydin C, Bahar K. J Viral Hepat. 2012 Mar;19(3):220-6. doi: 10.1111/j.1365-2893.2011.01542.x. Epub 2011 Oct 19.


  380. Antiviral therapy of decompensated hepatitis B virus-related cirrhosis
    Chen GC, Yu T, Huang KH, Chen QK. Chin Med J (Engl). 2012 Jan;125(2):373-7.


  381. Prognosis predictability of hepatocellular carcinoma according to staging systems in hepatitis B virus-endemic area
    Kang HY, Shin HD, Kim SB, Song IH. Clin Res Hepatol Gastroenterol. 2012 Feb 8. [Epub ahead of print]


  382. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs
    Chotiyaputta W, Hongthanakorn C, Oberhelman K, Fontana RJ, Licari T, Lok AS. J Viral Hepat. 2012 Mar;19(3):205-12. doi: 10.1111/j.1365-2893.2011.01494.x. Epub 2011 Jul 14.


  383. Safety and efficacy of two-step peginterferon ?-2a treatment in patients of chronic hepatitis B with acute exacerbation
    Chen CC, Wang PC, Chang HW, Chen CF. J Viral Hepat. 2012 Mar;19(3):161-72. doi: 10.1111/j.1365-2893.2011.01469.x. Epub 2011 Jul 4.


  384. Selection of chronic hepatitis B therapy with high barrier to resistance
    Gish R, Jia JD, Locarnini S, Zoulim F. Lancet Infect Dis. 2012 Feb 8. [Epub ahead of print]


  385. Quality of Life and the Relevant Factors in Patients with Chronic Hepatitis B
    Wang L, Wang Y, Tang L, Feng C, Liu X, Zhang R, Liu D. Hepatogastroenterology. 2012 Feb 10;59(116). doi: 10.5754/hge11867. [Epub ahead of print]


  386. Association of polymorphisms in interleukin-18 and interleukin-28B with Hepatitis B recurrence after liver transplantation in Chinese Han population
    Li Y, Shi Y, Chen J, Cai B, Ying B, Wang L. Int J Immunogenet. 2012 Feb 10. doi: 10.1111/j.1744-313X.2012.01097.x. [Epub ahead of print]


  387. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age
    Halperin SA, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, Embree J, McGeer A, Zickler P, Moltz KH, Martz R, Meyer I, McNeil S, Langley JM, Martins E, Heyward WL, Martin JT. Vaccine. 2012 Feb 8. [Epub ahead of print]


  388. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir
    Pan CQ, Hu KQ, Yu AS, Chen W, Bunchorntavakul C, Reddy KR. J Viral Hepat. 2012 Mar;19(3):213-9. doi: 10.1111/j.1365-2893.2011.01533.x. Epub 2011 Oct 17.


  389. Peginteferon-? does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis
    Penna A, Laccabue D, Libri I, Giuberti T, Schivazappa S, Alfieri A, Mori C, Canetti D, Lampertico P, Viganò M, Colombo M, Loggi E, Missale G, Ferrari C. J Hepatol. 2012 Feb 9. [Epub ahead of print]


  390. Treatment of chronic hepatitis B with nucleos(t)ide analogues
    Ohishi W, Chayama K. Hepatol Res. 2011 Dec 19. doi: 10.1111/j.1872-034X.2011.00921.x. [Epub ahead of print]


  391. Protective hepatitis B surface antibodies in blood and ascites fluid in the early stage after liver transplantation for hepatitis B diseases
    Wang K, Zhu ZJ, Zheng H, Deng YL, Pan C, Sun LY, Shen ZY. Hepatol Res. 2011 Dec 16. doi: 10.1111/j.1872-034X.2011.00926.x. [Epub ahead of print]


  392. Hepatitis B virus serology to predict antiviral response in chronic hepatitis B
    Kim BK, Han KH, Ahn SH. Digestion. 2011;84 Suppl 1:29-34. Epub 2011 Dec 2.


  393. Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma
    Izumi N. Hepatol Res. 2011 Dec 19. doi: 10.1111/j.1872-034X.2011.00922.x. [Epub ahead of print]


  394. Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients
    Kwak MS, Cho EJ, Jang ES, Lee JH, Yu SJ, Kim YJ, Yoon JH, Lee HS. Digestion. 2011;84 Suppl 1:23-8. Epub 2011 Dec 2.


  395. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management
    Viganò M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Expert Opin Biol Ther. 2011 Dec 22. [Epub ahead of print]


  396. Use of Hepatitis B Vaccination for Adults with Diabetes Mellitus: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011 Dec 23;60:1709-11.


  397. Effects of Maternal Screening and Universal Immunization to Prevent Mother-To-Infant Transmission of HBV
    Chen HL, Lin LH, Hu FC, Lee JT, Lin WT, Yang YJ, Huang FC, Wu SF, Chen SC, Wen WH, Chu CH, Ni YH, Hsu HY, Tsai PL, Chiang CL, Shyu MK, Lee PI, Chang FY, Chang MH. Gastroenterology. 2011 Dec 22. [Epub ahead of print]


  398. Restored circulating invariant NKT cells are associated with viral control in patients with chronic hepatitis B
    Jiang X, Zhang M, Lai Q, Huang X, Li Y, Sun J, Abbott WG, Ma S, Hou J. PLoS One. 2011;6(12):e28871. Epub 2011 Dec 16.


  399. Emerging pipeline drugs for hepatitis B infection
    Cox N, Tillmann H. Expert Opin Emerg Drugs. 2011 Dec;16(4):713-29.


  400. Use of Nucleoside (Tide) Analogues in Patients with Hepatitis B-Related Acute Liver Failure
    Dao DY, Seremba E, Ajmera V, Sanders C, Hynan LS, Lee WM; The Acute Liver Failure Study Group. Dig Dis Sci. 2011 Dec 25. [Epub ahead of print]


  401. Comparison of the Clinical Features of Hepatitis A between HBsAg-Positive and HBsAg-Negative Patients
    Kim KM, Eo SJ, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW. Gut Liver. 2011 Dec;5(4):500-5. Epub 2011 Nov 21.


  402. A systematic review of the fetal safety of interferon alpha
    Yazdani Brojeni P, Matok I, Garcia Bournissen F, Koren G. Reprod Toxicol. 2011 Dec 19. [Epub ahead of print]


  403. Factors predicting the efficacy of adefovir dipivoxil on treatment-naïve chronic hepatitis B patients at 48 weeks
    Wang LC, Chen EQ, Zhu XF, Xiong ZH, Liu L, Xu L, Lei XZ, Liu C, Tang H. Gut Liver. 2011 Dec;5(4):478-85. Epub 2011 Nov 21.


  404. Efficacy of High-Dose Intra-dermal Hepatitis B Virus Vaccine in Previous Vaccination Non-responders with Chronic Liver Disease
    Dhillon S, Moore C, Li SD, Aziz A, Kakar A, Dosanjh A, Beesla A, Murphy L, Van Thiel DH. Dig Dis Sci. 2011 Dec 9. [Epub ahead of print]


  405. Hepatitis B virus infection and the risk of hepatocellular carcinoma
    Tan YJ. World J Gastroenterol. 2011 Nov 28;17(44):4853-7.


  406. The Efficacy and Tolerability of Pegylated Interferon-?-2a in Chronic Hepatitis B: A Multicenter Clinical Experience
    Ratnam D, Dev A, Nguyen T, Sundararajan V, Harley H, Cheng W, Lee A, Rusli F, Chen R, Bell S, Pianko S, Sievert W. J Gastroenterol Hepatol. 2011 Dec 14. doi: 10.1111/j.1440-1746.2011.07051.x. [Epub ahead of print]


  407. The increasing burden of imported chronic hepatitis B - United States, 1974-2008
    Mitchell T, Armstrong GL, Hu DJ, Wasley A, Painter JA. PLoS One. 2011;6(12):e27717. Epub 2011 Dec 7.


  408. Traditional Chinese Medicine Syndrome Distribution in Chronic Hepatitis B Populations: A Systematic Review
    Zeng XX, Bian ZX, Wu TX, Fu SF, Ziea E, Woon WT. Am J Chin Med. 2011 2011;39(6):1061-1074.


  409. A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study: Adefovir versus Entercavir for Chronic Hepatitis B
    Chen EQ, Zhou TY, Liu L, Liu C, Lei M, Tang H. Hepat Mon. 2011 Jan 1;11(1):27-31.


  410. An Algorithm for Risk Assessment and Intervention of Mother to Child Transmission of Hepatitis B Virus
    Pan CQ, Duan Z, Bhamidimarri KR, Zou H, Liang X, Li J, Tong MJ. Clin Gastroenterol Hepatol. 2011 Nov 8. [Epub ahead of print]


  411. Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity
    Cassidy A, Mossman S, Olivieri A, Ridder MD, Leroux-Roels G. Expert Rev Vaccines. 2011 Dec;10(12):1709-1715.


  412. Use of anti-tumor necrosis factor-? therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: A case series in Taiwan
    Cho YT, Chen CH, Chiu HY, Tsai TF. J Dermatol. 2011 Nov 14. doi: 10.1111/j.1346-8138.2011.01434.x. [Epub ahead of print]


  413. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes
    Vassilopoulos D. Eur J Intern Med. 2011 Dec;22(6):572-5. Epub 2011 Sep 25.


  414. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? NO
    Marignani M, Canzoni M, D'Amelio R, De Santis E, Pecchioli A, Delle Fave G. Eur J Intern Med. 2011 Dec;22(6):576-81. Epub 2011 Sep 25.


  415. The asian american hepatitis B program: building a coalition to address hepatitis B health disparities
    Trinh-Shevrin C, Pollack HJ, Tsang T, Park J, Ramos MR, Islam N, Wang S, Chun K, Sim SC, Pong P, Rey MJ, Kwon SC. Prog Community Health Partnersh. 2011 Fall;5(3):261-71.


  416. Recent advances in the management of chronic hepatitis B
    Kim SR, Yang J, Kudo M, Hino O. Hepat Mon. 2011 Aug 1;11(8):601-11.


  417. Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease
    Keating GM. Drugs. 2011 Dec 24;71(18):2511-29. doi: 10.2165/11208510-000000000-00000.


  418. Prevention of Hepatitis B Recurrence in Liver Transplant Patients Using Oral Antiviral Therapy without Long-Term Hepatitis B Immunoglobulin
    Ahn J, Cohen SM. Hepat Mon. 2011 Aug 1;11(8):638-45.


  419. Progress in newborn hepatitis B vaccination by birth year cohorts-1998-2007, USA
    Zhao Z, Murphy TV, Jacques-Carroll L. Vaccine. 2011 Nov 4. [Epub ahead of print]


  420. Viral adaptation to host immune responses occurs in chronic hepatitis B virus infection and adaptation is greatest in HBeAg negative disease
    Desmond CP, Gaudieri S, James IR, Pfafferott K, Chopra A, Lau GK, Audsley J, Day C, Chivers S, Gordon A, Revill PA, Bowden S, Ayres A, Desmond PV, Thompson AJ, Roberts SK, Locarnini SA, Mallal SA, Lewin SR. J Virol. 2011 Nov 9. [Epub ahead of print]


  421. Protective Effect of Hepatitis B Vaccine Combined with Two-Dose Hepatitis B Immunoglobulin on Infants Born to HBsAg-Positive Mothers
    Zou H, Chen Y, Duan Z, Zhang H. PLoS One. 2011;6(10):e26748. Epub 2011 Oct 28.


  422. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin
    Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Hepatology. 2011 Nov 22. doi: 10.1002/hep.24804. [Epub ahead of print]


  423. Polymorphisms Near IL28B and Serological Response to Peginterferon in HBeAg-Positive Patients with Chronic Hepatitis B
    Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL. Gastroenterology. 2011 Nov 18. [Epub ahead of print]


  424. Is There Any Value to Hepatitis B Virus Genotype Analysis?
    Tanwar S, Dusheiko G. Curr Gastroenterol Rep. 2011 Nov 22. [Epub ahead of print]


  425. Report on a single topic conference on
    Ward JW, Lok AS, Thomas DL, El-Serag HB, Kim WR. Hepatology. 2011 Nov 22. doi: 10.1002/hep.24797. [Epub ahead of print]


  426. Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B
    Ate? F, Yaln?z M, Alan S. World J Gastroenterol. 2011 Oct 28;17(40):4517-22.


  427. Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers
    Park H, Lee JM, Seo JH, Kim HS, Ahn SH, Kim DY, Han KH, Chon CY, Park JY. Liver Int. 2011 Nov 30. doi: 10.1111/j.1478-3231.2011.02693.x. [Epub ahead of print]


  428. Serum levels of interleukin-12 in various clinical states with hepatitis B virus infection
    He D, Yan G, Wang Y. Cell Immunol. 2011 Nov 2. [Epub ahead of print]


  429. Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety
    Lam YF, Yuen MF, Seto WK, Lai CL. Curr Hepat Rep. 2011 Dec;10(4):235-243. Epub 2011 Aug 9.


  430. Efficacy of Entecavir and Adefovir Combination Therapy for Patients with Lamivudine- and Entecavir-Resistant Chronic Hepatitis B
    Jeon JW, Shin HP, Lee JI, Joo KR, Cha JM, Park JJ, Lim JU, Lim K, Kim S. Dig Dis Sci. 2011 Dec 2. [Epub ahead of print]


  431. The role of liver fibrosis assessment in the management of patients with chronic hepatitis B infection: lessons learned from a single centre experience
    Malik R, Kennedy P, Suri D, Brown A, Goldin R, Main J, Thomas H, Thursz M. Hepat Res Treat. 2011;2011:524027. Epub 2011 Oct 30.


  432. Hepatitis B prevention, diagnosis, treatment and care: a review
    Aspinall EJ, Hawkins G, Fraser A, Hutchinson SJ, Goldberg D. Occup Med (Lond). 2011 Dec;61(8):531-40.


  433. Entecavir Plus Tenofovir Combination as Rescue Therapy in Pretreated Chronic Hepatitis B Patients. An International Multicenter Cohort Study
    Petersen J, Ratziu V, Buti M, Janssen HL, Brown A, Lampertico P, Schollmeyer J, Zoulim F, Wedemeyer H, Sterneck M, Berg T, Sarrazin C, Lutgehetmann M, Buggisch P. J Hepatol. 2011 Oct 26. [Epub ahead of print]


  434. Hepatitis B virus infection and replication in human bone marrow mesenchymal stem cells
    Ma R, Xing Q, Shao L, Wang D, Hao Q, Li X, Sai L, Ma L. Virol J. 2011 Oct 31;8(1):486. [Epub ahead of print]


  435. Prevalence of and Risk Factors for Hepatitis B Viremia After Spontaneous Hepatitis B Surface Antigen Seroclearance in Hepatitis B Carriers
    Chu CM, Liaw YF. Clin Infect Dis. 2011 Nov 3. [Epub ahead of print]


  436. GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals
    Overton ET, Sungkanuparph S, Klebert M, Royal M, Demarco-Shaw D, Powderly WG, Aberg JA. Open Virol J. 2011;5:109-13. Epub 2011 Oct 14.


  437. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: Randomized study in healthy girls
    Schmeink CE, Bekkers RL, Josefsson A, Richardus JH, Berndtsson Blom K, David MP, Dobbelaere K, Descamps D. Vaccine. 2011 Aug 19. [Epub ahead of print]


  438. Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatitis B After 2 Years of Entecavir Treatment
    Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, Yuen MF. Am J Gastroenterol. 2011 Aug 9. doi: 10.1038/ajg.2011.253. [Epub ahead of print]


  439. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma
    Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, Su J, Hsiao CK, Wang LY, You SL, Lu SN, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (REVEAL–HBV) Study Group. Gastroenterology. 2011 Oct;141(4):1240-1248.e2. Epub 2011 Jun 22.


  440. Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies
    Zhou Y, Si X, Wu L, Su X, Li B, Zhang Z. World J Surg Oncol. 2011 Sep 21;9:108.


  441. Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients
    Moses SE, Lim Z, Zuckerman MA. Expert Rev Anti Infect Ther. 2011 Oct;9(10):891-9.


  442. Review article: current antiviral therapy of chronic hepatitis B
    Ayoub WS, Keeffe EB. Aliment Pharmacol Ther. 2011 Oct 7. doi: 10.1111/j.1365-2036.2011.04869.x. [Epub ahead of print]


  443. Prospective evaluation of seropositive occult hepatitis B viral infection in lymphoma patients receiving chemotherapy
    Cheung WI, Lin SY, Leung VK, Fung KS, Lam YK, Lo FH, Chau TN. Hong Kong Med J. 2011 Oct;17(5):376-80.


  444. Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B
    Ahn SH, Kweon YO, Paik SW, Sohn JH, Lee KS, Kim DJ, Piratvisuth T, Yuen MF, Chutaputti A, Chao YC, Trylesinski A, Avila C. Hepatol Int. 2011 Oct 12. [Epub ahead of print]


  445. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy
    Chung GE, Kim W, Lee JH, Kim YJ, Yoon JH, Lee JM, Lee JY, Kim SH, Kim D, Lee HS. J Gastroenterol Hepatol. 2011 Nov;26(11):1638-1645. doi: 10.1111/j.1440-1746.2011.06777.x.


  446. Serum hepatitis B surface antigen levels in the natural history of chronic hepatitis B infection
    Jang JW, Yoo SH, Kwon JH, You CR, Lee S, Lee JH, Chung KW. Aliment Pharmacol Ther. 2011 Oct 19. doi: 10.1111/j.1365-2036.2011.04888.x. [Epub ahead of print]


  447. Clinical study on prevention of HBV re-infection by entecavir after liver transplantation
    Cai CJ, Lu MQ, Chen YH, Zhao H, Li MR, Chen GH. Clin Transplant. 2011 Oct 10. doi: 10.1111/j.1399-0012.2011.01448.x. [Epub ahead of print]


  448. Screening High Risk Individuals for Hepatitis B: Physician Knowledge, Attitudes, and Beliefs
    Foster T, Hon H, Kanwal F, Han S, Spiegel B. Dig Dis Sci. 2011 Oct 15. [Epub ahead of print]


  449. Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B
    Kim SS, Cheong JY, Lee D, Lee MH, Hong SP, Kim SO, Cho SW. J Med Virol. 2011 Oct 25. doi: 10.1002/jmv.22227. [Epub ahead of print]


  450. Reactivated hepatitis B due to medical interventions: the clinical spectrum expands
    Perrillo RP. Antivir Ther. 2011;16(7):947-9.


  451. Current trends in management of hepatitis B virus reactivation in the biologic therapy era
    Mastroianni CM, Lichtner M, Citton R, Borgo CD, Rago A, Martini H, Cimino G, Vullo V. World J Gastroenterol. 2011 Sep 14;17(34):3881-7.


  452. Liver Transplantation from Hepatitis B Surface Antigen Positive Donors: A Safe Way to Expand the Donor Pool
    Loggi E, Micco L, Ercolani G, Cucchetti A, Bihl FK, Grazi GL, Gitto S, Bontadini A, Bernardi M, Grossi P, Costa AN, Pinna AD, Brander C, Andreone P. J Hepatol. 2011 Oct 22. [Epub ahead of print]


  453. Current status of liver transplantation for hepatitis B virus
    Buchanan C, Tran TT. Clin Liver Dis. 2011 Nov;15(4):753-64.


  454. Hepatitis B virus infection and fatty liver in the general population
    Wong VW, Wong GL, Chu WC, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Chan HY, Woo J, Chan FK, Chan HL. J Hepatol. 2011 Oct 22. [Epub ahead of print]


  455. Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: a prospective comparison of prophylactic versus deferred preemptive lamivudine
    Tsai SH, Dai MS, Yu JC, Ho CL, Chen YC, Wu YY, Chang PY, Kao WY, Chao TY. Support Care Cancer. 2011 Nov;19(11):1779-87. Epub 2010 Oct 7.


  456. Outcome of Liver Transplantation for Recipients With Hepatitis B and Hepatitis C Virus Coinfection: Analysis of the UNOS Data
    Waki K, Sugawara Y, Tamura S, Mieno MN, Yamashiki N, Kadowaki T, Kokudo N. Transplantation. 2011 Oct 15;92(7):809-814.


  457. Doing Good with Good OR: Supporting Cost-effective Hepatitis B Interventions
    Hutton DW, Brandeau ML, So SK. Interfaces (Providence). 2011 May;41(3):289-300.


  458. Virological response to adefovir monotherapy and the risk of adefovir resistance
    Sinn DH, Lee HI, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. World J Gastroenterol. 2011 Aug 14;17(30):3526-3530.


  459. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir
    Kwak MS, Choi JW, Lee JS, Kim KA, Suh JH, Cho YS, Won SY, Park BK, Lee CK. J Viral Hepat. 2011 Oct;18(10):e432-8. doi: 10.1111/j.1365-2893.2011.01461.x. Epub 2011 May 13.


  460. Sensitivity comparison of two Food and Drug Administration-licensed, triplex nucleic acid test automated assays for hepatitis B virus DNA detection and associated projections of United States yield
    Stramer SL, Krysztof DE, Brodsky JP, Fickett TA, Reynolds B, Phikulsod S, Oota S, Lin M, Saldanha J, Kleinman SH. Transfusion. 2011 Sep;51(9):2012-22. doi: 10.1111/j.1537-2995.2011.03140.x. Epub 2011 Apr 19.


  461. Role of sociocultural factors in hepatitis B screening among asian americans
    Ma GX, Lee S, Wang M, Tan Y, Gao W, Ma X, Lai P, Toubbeh JI. South Med J. 2011 Jul;104(7):466-72.


  462. The Management of Chronic Hepatitis B in Asian Americans
    Tong MJ, Pan CQ, Hann HW, Kowdley KV, Han SH, Min AD, Leduc TS. Dig Dis Sci. 2011 Sep 21. [Epub ahead of print]


  463. Clinical importance of serum hepatitis B surface antigen levels in chronic hepatitis B
    Togo S, Arai M, Tawada A, Chiba T, Kanda T, Fujiwara K, Imazeki F, Yokosuka O. J Viral Hepat. 2011 Oct;18(10):e508-15. doi: 10.1111/j.1365-2893.2011.01486.x. Epub 2011 Jul 22.


  464. Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists
    Day FL, Link E, Thursky K, Rischin D. J Oncol Pract. 2011 May;7(3):141-7.


  465. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings
    Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, Iodice V, Sagnelli C, Stanzione M, Capoluongo N, Pasquale G, Sagnelli E. J Med Virol. 2011 Nov;83(11):1909-16. doi: 10.1002/jmv.22199. Epub 2011 Aug 23.


  466. Evolution of hepatitis B virus during long-term therapy in patients with chronic hepatitis B
    Arrese E, Basaras M, Blanco S, Ruiz P, Cisterna R. Ann Hepatol. 2011 Oct 1;10(4):434-40.


  467. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference
    Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M, Delarocque-Astagneau E, Dusheiko G, Esmat G, Esteban R, Goldberg D, Gore C, Lok AS, Manns M, Marcellin P, Papatheodoridis G, Peterle A, Prati D, Piorkowsky N, Rizzetto M, Roudot-Thoraval F, Soriano V, Thomas HC, Thursz M, Valla D, van Damme P, Veldhuijzen IK, Wedemeyer H, Wiessing L, Zanetti AR, Janssen HL. J Viral Hepat. 2011 Sep;18 Suppl 1:1-16. doi: 10.1111/j.1365-2893.2011.01499.x.


  468. Balancing Donor and Recipient Risk Factors in Liver Transplantation: The Value of D-MELD with Particular Reference to HCV Recipients
    Avolio AW, Cillo U, Salizzoni M, De Carlis L, Colledan M, Gerunda GE, Mazzaferro V, Tisone G, Romagnoli R, Caccamo L, Rossi M, Vitale A, Cucchetti A, Lupo L, Gruttadauria S, Nicolotti N, Burra P, Gasbarrini A, Agnes S; On behalf of the Donor-to-Recipient Italian Liver Transplant (D2R-ILTx) Study Group. Am J Transplant. 2011 Sep 15. doi: 10.1111/j.1600-6143.2011.03732.x. [Epub ahead of print]


  469. Reactivation of resolved hepatitis B virus infection after immunosuppression: Is it time to adopt pre-emptive therapy?
    Papamichalis P, Alexiou A, Boulbou M, Dalekos GN, Rigopoulou EI. Clin Res Hepatol Gastroenterol. 2011 Sep 13. [Epub ahead of print]


  470. Does antiviral therapy prevent hepatocellular carcinoma?
    Kwon H, Lok AS. Antivir Ther. 2011;16(6):787-95.


  471. Decreasing Levels of HBsAg Predict HBsAg Seroclearance in Patients with Inactive Chronic Hepatitis B Virus Infection
    Chen YC, Jeng WJ, Chu CM, Liaw YF. Clin Gastroenterol Hepatol. 2011 Sep 2. [Epub ahead of print]


  472. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir
    Kwak MS, Choi JW, Lee JS, Kim KA, Suh JH, Cho YS, Won SY, Park BK, Lee CK. J Viral Hepat. 2011 Oct;18(10):e432-8. doi: 10.1111/j.1365-2893.2011.01461.x. Epub 2011 May 13.


  473. Risk Factors for Early-Onset and Late-Onset Hepatocellular Carcinoma in Asian Immigrants With Hepatitis B in the United States
    Wan DW, Tzimas D, Smith JA, Kim S, Araujo J, David R, Lobach I, Sarpel U. Am J Gastroenterol. 2011 Sep 13. doi: 10.1038/ajg.2011.302. [Epub ahead of print]


  474. Chronic hepatitis B infection: A workshop consensus statement and algorithm
    McHugh JA, Cullison S, Apuzzio J, Block JM, Cohen C, Leong SL, London WT, McNellis RJ, Neubauer RL, Perrillo R, Squires R, Tarrant D, McMahon BJ. J Fam Pract. 2011 Sep;60(9):E1-8.


  475. Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance
    Park JW, Kim HS, Seo DD, Jang JS, Shin WG, Kim KH, Jang MK, Lee JH, Kim HY, Kim DJ, Lee MS, Park CK. J Viral Hepat. 2011 Oct;18(10):e475-81. doi: 10.1111/j.1365-2893.2011.01479.x. Epub 2011 Jun 1.


  476. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir
    Ong A, Wong VW, Wong GL, Chan HY, Tse CH, Chan HL. Aliment Pharmacol Ther. 2011 Aug 24. doi: 10.1111/j.1365-2036.2011.04833.x. [Epub ahead of print]


  477. Role of sociocultural factors in hepatitis B screening among asian americans
    Ma GX, Lee S, Wang M, Tan Y, Gao W, Ma X, Lai P, Toubbeh JI. South Med J. 2011 Jul;104(7):466-72.


  478. Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists
    Day FL, Link E, Thursky K, Rischin D. J Oncol Pract. 2011 May;7(3):141-7.


  479. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma
    Jin YJ, Shim JH, Lee HC, Yoo DJ, Kim KM, Lim YS, Suh DJ. J Gastroenterol Hepatol. 2011 Sep;26(9):1380-8. doi: 10.1111/j.1440-1746.2011.06776.x.


  480. National and state vaccination coverage among children aged 19--35 months --- United States, 2010
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011 Sep 2;60:1157-63.


  481. Viral hepatitis B, active component, U.S. Armed Forces, 2000-2010
    Armed Forces Health Surveillance Center (AFHSC). MSMR. 2011 Aug;18(8):5-9.


  482. Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants
    Lee AW, Vesikari T, Gilbert CL, Klopfer SO, Schödel FP, Bhuyan PK. Vaccine. 2011 Aug 26. [Epub ahead of print]


  483. Determinants of spontaneous surface antigen loss in HBeAg-negative patients with a low viral load
    Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Hepatology. 2011 Aug 19. doi: 10.1002/hep.24615. [Epub ahead of print]


  484. Is Transient Elastography Valuable for High Risk Esophageal Varices Prediction in Patients with Hepatitis B Related Cirrhosis?
    Chen YP, Zhang Q, Dai L, Liang XE, Peng J, Hou JL. J Gastroenterol Hepatol. 2011 Aug 22. doi: 10.1111/j.1440-1746.2011.06889.x. [Epub ahead of print]


  485. Donor Testing and Risk: Current Prevalence, Incidence, and Residual Risk of Transfusion-Transmissible Agents in US Allogeneic Donations
    Zou S, Stramer SL, Dodd RY. Transfus Med Rev. 2011 Aug 24. [Epub ahead of print]


  486. Genotypic Distribution of Hepatitis B Virus (HBV) Among Acute Cases of HBV Infection, Selected US Counties, 1999-2005
    Teshale EH, Ramachandran S, Xia GL, Roberts H, Groeger J, Barry V, Hu DJ, Holmberg SD, Holtzman D, Ward JW, Teo CG, Khudyakov Y. Clin Infect Dis. 2011 Aug 22. [Epub ahead of print]


  487. Can self-prediction overcome barriers to hepatitis B vaccination? A randomized controlled trial
    Cox AD, Cox D, Cyrier R, Graham-Dotson Y, Zimet GD. Health Psychol. 2011 Aug 29. [Epub ahead of print]


  488. Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure
    Huang K, Hu JH, Wang HF, He WP, Chen J, Duan XZ, Zhang AM, Liu XY. World J Gastroenterol. 2011 Aug 7;17(29):3448-52.


  489. Risk Factors for Liver Disease and Associated Knowledge and Practices Among Mexican Adults in the US and Mexico
    Flores YN, Lang CM, Salmerón J, Bastani R. J Community Health. 2011 Aug 30. [Epub ahead of print]


  490. Cost-effectiveness of maternal treatment to prevent perinatal hepatitis B virus transmission
    Unal ER, Lazenby GB, Lintzenich AE, Simpson KN, Newman R, Goetzl L. Obstet Gynecol. 2011 Sep;118(3):655-62.


  491. Using Survey Results Regarding Hepatitis B Knowledge, Community Awareness and Testing Behavior Among Asians to Improve the San Francisco Hep B Free Campaign
    Shiau R, Bove F, Henne J, Zola J, Fang T, Fernyak S. J Community Health. 2011 Aug 27. [Epub ahead of print]


  492. Awareness, perceptions and knowledge of recommended adult vaccines among a nationwide sample of adult primary care providers
    Tan TQ, Bhattacharya L, Gerbie MV. J Reprod Med. 2011 Jul-Aug;56(7-8):301-7.


  493. Hepatitis B Virus Reactivation by Immunosuppressive Therapy in Patients with Autoimmune Diseases: Risk Analysis in Hepatitis B Surface Antigen-negative Cases
    Kato M, Atsumi T, Kurita T, Odani T, Fujieda Y, Otomo K, Horita T, Yasuda S, Koike T. J Rheumatol. 2011 Aug 15. [Epub ahead of print]


  494. Prophylaxis of hepatitis B reactivation with immunosuppressive therapy in rheumatic diseases. Orientations for clinical practice
    Nunes J, Marinho RT, Fonseca JE, Pereira da Silva JA, Velosa J. Acta Reumatol Port. 2011 Abr-Jun;36(2):110-118.


  495. High prevalence of hepatitis B virus infection in multiple myeloma
    Huang B, Li J, Zhou Z, Zheng D, Liu J, Chen M. Leuk Lymphoma. 2011 Aug 8. [Epub ahead of print]


  496. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
    Sheng YJ, Liu JY, Tong SW, Hu HD, Zhang DZ, Hu P, Ren H. Virol J. 2011 Aug 8;8(1):393. [Epub ahead of print]


  497. ABO blood group, hepatitis B viral infection, and risk of pancreatic cancer
    Wang DS, Chen DL, Ren C, Wang ZQ, Qiu MZ, Luo HY, Zhang DS, Wang FH, Li YH, Xu RH. Int J Cancer. 2011 Aug 19. doi: 10.1002/ijc.26376. [Epub ahead of print]


  498. Influencing factors of mother-infant vertical transmission of hepatitis B virus
    Zhang WL, Zhao J, Li W. Zhongguo Dang Dai Er Ke Za Zhi. 2011 Aug;13(8):644-6.


  499. A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B
    Seto WK, Lee CF, Lai CL, Ip PP, Fong DY, Fung J, Wong DK, Yuen MF. PLoS One. 2011;6(8):e23077. Epub 2011 Aug 11.


  500. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: Randomized study in healthy girls
    Schmeink CE. Vaccine. 2011 Aug 18. [Epub ahead of print]


  501. Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding
    Giles M, Visvanathan K, Sasadeusz J. Antivir Ther. 2011;16(5):621-8.


  502. Reduction of liver stiffness by antiviral therapy in chronic hepatitis B
    Osakabe K, Ichino N, Nishikawa T, Sugiyama H, Kato M, Kitahara S, Hashimoto S, Kawabe N, Harata M, Nitta Y, Murao M, Nakano T, Shimazaki H, Arima Y, Suzuki K, Yoshioka K. J Gastroenterol. 2011 Aug 6. [Epub ahead of print]


  503. Validity of parent-reported vaccination status for adolescents aged 13-17 years: national immunization survey-teen, 2008
    Dorell CG, Jain N, Yankey D. Public Health Rep. 2011 Jul-Aug;126 Suppl 2:60-9.


  504. Improving immunization rates at 18 months of age: implications for individual practices
    McElligott JT, Roberts JR, O'Brien ES, Freeland KD, Kolasa MS, Stevenson J, Darden PM. Public Health Rep. 2011 Jul-Aug;126 Suppl 2:33-8.


  505. Vaccination coverage among U.S. children aged 19-35 months entitled by the Vaccines for Children program, 2009
    Smith PJ, Lindley MC, Rodewald LE. Public Health Rep. 2011 Jul-Aug;126 Suppl 2:109-23.


  506. HBV-carriers: When is monitoring and surveillance sufficient? (point of view)
    Andreani T. Clin Res Hepatol Gastroenterol. 2011 Aug 5. [Epub ahead of print]


  507. A latest and promising approach for prediction of viral load in hepatitis B virus infected patients
    Yalamanchili N, Syed R, Chandra M, Satti V, Rao R, Mohammed AH, Nanne KM. Indian J Hum Genet. 2011 Jan;17(1):17-21.


  508. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination
    Zhu CL, Liu P, Chen T, Ni Z, Lu LL, Huang F, Lu J, Sun Z, Qu C. Vaccine. 2011 Aug 1. [Epub ahead of print]


  509. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review
    Liaw YF. Hepatology. 2011 Aug;54(2):E1-9. doi: 10.1002/hep.24473.


  510. Hepatitis B immunoglobulin for prevention of hepatitis B virus infection and recurrence after liver transplantation
    Congly SE, Burak KW, Coffin CS. Expert Rev Clin Immunol. 2011 Jul;7(4):429-36.


  511. Use of biological DMARDs in patients with concurrent rheumatic disease and hepatitis B
    King LK, Lee A, Anandacoomarasamy A. Intern Med J. 2011 Jul 25. doi: 10.1111/j.1445-5994.2011.02569.x. [Epub ahead of print]


  512. Liver Stiffness Measurement and Biochemical Markers in Senegalese Chronic Hepatitis B Patients with Normal ALT and High Viral Load
    Mbaye PS, Sarr A, Sire JM, Evra ML, Ba A, Daveiga J, Diallo A, Fall F, Chartier L, Simon F, Vray M. PLoS One. 2011;6(7):e22291. Epub 2011 Jul 25.


  513. Cost-Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Solid Tumors
    Day FL, Karnon J, Rischin D. J Clin Oncol. 2011 Jul 25. [Epub ahead of print]


  514. Prevalence of Hepatitis B Infection Among Young and Unsuspecting Hmong Blood Donors in the Central California Valley
    Sheikh MY, Atla PR, Raoufi R, Sadiq H, Sadler PC. J Community Health. 2011 Jul 22. [Epub ahead of print]


  515. Preventing Hepatitis B-induced Liver Cancer: Implications for Eliminating Health Disparities
    Chen MS Jr. J Health Dispar Res Pract. 2010 Oct 1;4(2):88-99.


  516. An overview of Triple infection with Hepatitis B, C and D viruses
    Riaz M, Idrees M, Kanwal H, Kabir F. Virol J. 2011 Jul 27;8(1):368. [Epub ahead of print]


  517. Hepatitis B vaccination coverage among high-risk adults 18-49 years, U.S., 2009
    Lu PJ, Byrd KK, Murphy TV, Weinbaum C. Vaccine. 2011 Jul 20. [Epub ahead of print]


  518. The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography
    Ong A, Wong VW, Wong GL, Chan HL. Liver Int. 2011 Aug;31(7):1047-53. doi: 10.1111/j.1478-3231.2011.02555.x. Epub 2011 May 31.


  519. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis
    Shi Y, Wu YH, Wei W, Zhang WJ, Yang J, Chen Z. Liver Int. 2011 Feb 23. doi: 10.1111/j.1478-3231.2011.02481.x. [Epub ahead of print]


  520. Noninvasive diagnostic criteria for hepatocellular carcinoma in hepatic masses >2?cm in a hepatitis B virus-endemic area
    Kim SE, Lee HC, Shim JH, Park HJ, Kim KM, Kim PN, Shin YM, Yu ES, Chung YH, Suh DJ. Liver Int. 2011 Apr 11. doi: 10.1111/j.1478-3231.2011.02529.x. [Epub ahead of print]


  521. The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up
    Hu TH, Tsai MC, Chen YT, Chien YS, Hung CH, Chen TC, Tseng PL, Chang KC, Yen YH.


  522. Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B
    Wong VW, Wong GL, Tse CH, Yuen LK, Chan HY, Locarnini SA, Chan HL. Dig Dis Sci. 2011 Jul 9. [Epub ahead of print]


  523. A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol
    Xie W, Shi G, Zhang H, Zhao G, Yu Z, Lang Z, Zhao H, Yan J, Cheng J. Hepatol Int. 2011 Jul 20. [Epub ahead of print] Source Liver Center, Beijing Ditan Hospital, Capital Medical University, 100015, Beijing, China.


  524. Update on childhood and adolescent immunizations: selected review of US recommendations and literature: part 1
    Fay KE, Lai J, Bocchini JA Jr. Curr Opin Pediatr. 2011 Aug;23(4):460-9


  525. Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study
    Si-Ahmed SN, Pradat P, Zoutendijk R, Buti M, Mallet V, Cruiziat C, Deterding K, Dumortier J, Bailly F, Esteban R, Wedemeyer H, Janssen HL, Zoulim F. Antiviral Res. 2011 Jul 15. [Epub ahead of print]


  526. Cost effectiveness of screening immigrants for hepatitis B
    Wong WW, Woo G, Jenny Heathcote E, Krahn M. Liver Int. 2011 Jun 14. doi: 10.1111/j.1478-3231.2011.02559.x. [Epub ahead of print]


  527. Hepatitis B Vaccination Coverage and Documented Seroprotection among Matriculating Healthcare Students at an Academic Institution in the United States
    Tohme RA, Ribner B, Huey MJ, Spradling PR. Infect Control Hosp Epidemiol. 2011 Aug;32(8):818-21.


  528. Serum markers for necroinflammatory activity in patients with chronic viral hepatitis and normal or mildly elevated aminotransferase levels
    Cheong JY, Kim DJ, Hwang SG, Yang JM, Kim YB, Park YN, Cho SW. Liver Int. 2011 Jun 23. doi: 10.1111/j.1478-3231.2011.02570.x. [Epub ahead of print]


  529. Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice
    Ridruejo E, Adrover R, Cocozzella D, Reggiardo MV, Estepo C, Schroder T, Paz S, Mendizábal M, Fainboim H, Mandó OG, Silva MO. Int J Clin Pract. 2011 Aug;65(8):866-870. doi: 10.1111/j.1742-1241.2011.02719.x.


  530. Entecavir Monotherapy is Eeffective in Suppressing Hepatitis B Virus after Liver Transplantation
    Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, Dai WC, Chan AC, Cheung TT, Tsang S, Lam B, Lai CL, Lo CM. Gastroenterology. 2011 Jul 12. [Epub ahead of print]


  531. Frequency and Risk Factors of Renal Impairment During Long-term Adefovir Dipivoxil Treatment in Chronic Hepatitis B Patients
    Kim YJ, Cho HC, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. J Gastroenterol Hepatol. 2011 Jul 20. doi: 10.1111/j.1440-1746.2011.06852.x. [Epub ahead of print]


  532. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15-59 years of age
    Ray P, Black S, Shinefield H, Dillon A, Carpenter D, Lewis E, Ross P, Chen RT, Klein NP, Baxter R; for the Vaccine Safety Datalink Team. Vaccine. 2011 Jul 13. [Epub ahead of print] Source Kaiser Permanente Vaccine Study Center, Oakland, CA, USA.


  533. Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission
    Lin CL, Tseng TC, Su TH, Liu CJ, Chen PJ, Lai MY, Chen DS, Kao JH. Hepatol Int. 2011 Jul 21. [Epub ahead of print]


  534. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis
    Shi Y, Wu YH, Wei W, Zhang WJ, Yang J, Chen Z. Liver Int. 2011 Feb 23. doi: 10.1111/j.1478-3231.2011.02481.x. [Epub ahead of print]


  535. High Rate of Complete Viral Suppression With Combination Therapy in Patients With Chronic Hepatitis B and Prior Treatment Failure
    Wong CR, Trinh HN, Yip B, Nguyen HA, Garcia RT, Ahmed A, Keeffe EB, Nguyen MH. J Clin Gastroenterol. 2011 Jul 20. [Epub ahead of print]


  536. Comparison of noninvasive models of fibrosis in chronic hepatitis B
    Raftopoulos SC, George J, Bourliere M, Rossi E, de Boer WB, Jeffrey GP, Bulsara M, Speers DJ, Macquillan G, Ching HL, Kontorinis N, Cheng W, Flexman J, Fermoyle S, Rigby P, Walsh L, McLeod D, Adams LA. Hepatol Int. 2011 Jul 12. [Epub ahead of print]


  537. Long-term effect of maternal HBeAg on delayed HBeAg seroconversion in offspring with chronic hepatitis B infection
    Tseng YR, Wu JF, Ni YH, Chen HL, Chen CC, Wen WH, Hsu HY, Chang MH. Liver Int. 2011 Jun 28. doi: 10.1111/j.1478-3231.2011.02574.x. [Epub ahead of print]


  538. High Rate of Complete Viral Suppression With Combination Therapy in Patients With Chronic Hepatitis B and Prior Treatment Failure
    Wong CR, Trinh HN, Yip B, Nguyen HA, Garcia RT, Ahmed A, Keeffe EB, Nguyen MH. J Clin Gastroenterol. 2011 Jul 20. [Epub ahead of print]


  539. HBV DNA Loss within 24 Weeks Predicts Late Viral Breakthrough in Chronic Hepatitis B
    Jeon SR, Jang JY, Jeong SW, Park SH, Lee SH, Kim SG, Cheon YK, Kim YS, Cho YD, Moon JH, Kim HS, Lee JS, Kim BS. Korean J Gastroenterol. 2011 Jul 25;58(1):25-30.


  540. Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes
    Connell LE, Salihu HM, Salemi JL, August EM, Weldeselasse H, Mbah AK. Liver Int. 2011 Jun 7. doi: 10.1111/j.1478-3231.2011.02556.x. [Epub ahead of print]


  541. Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission
    Lin CL, Tseng TC, Su TH, Liu CJ, Chen PJ, Lai MY, Chen DS, Kao JH. Hepatol Int. 2011 Jul 21. [Epub ahead of print]


  542. An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients
    Zhang X, Lin SM, Ye F, Chen TY, Liu M, Chen YR, Zheng SQ, Zhao YR, Zhang SL. J Viral Hepat. 2011 Jul;18(7):e184-90. doi: 10.1111/j.1365-2893.2010.01423.x. Epub 2011 Jan 13.


  543. Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B
    Zhang NP, Reijnders JG, Perquin M, Hansen BE, Janssen HL. J Viral Hepat. 2011 Jul;18(7):e252-7. doi: 10.1111/j.1365-2893.2011.01448.x. Epub 2011 Mar 1.


  544. Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B
    Sanai FM, Helmy A, Bzeizi KI, Babatin MA, Al-Qahtani A, Al-Ashgar HA, Al-Mdani AS, Al-Akwaa A, Almutharea S, Khan MQ, Alghamdi AS, Farah T, Al-Hamoudi W, Saadeh M, Abdo AA. J Viral Hepat. 2011 Jul;18(7):e217-e225. doi: 10.1111/j.1365-2893.2011.01437.x. Epub 2011 Mar 1.


  545. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance
    Sun J, Hou JL, Xie Q, Li XH, Zhang JM, Wang YM, Wang H, Lai JY, Chen SJ, Jia JD, Sheng JF, Chan HL, Wang JF, Li MK, Jiang M, Popescu M, Sung JJ. Aliment Pharmacol Ther. 2011 Jun 22. doi: 10.1111/j.1365-2036.2011.04750.x. [Epub ahead of print]


  546. Pregnancy outcomes associated with viral hepatitis
    Reddick KL, Jhaveri R, Gandhi M, James AH, Swamy GK. J Viral Hepat. 2011 Jul;18(7):e394-8. doi: 10.1111/j.1365-2893.2011.01436.x. Epub 2011 Feb 8.


  547. Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study
    Fung J, Lai CL, Wong DK, Seto WK, Hung I, Yuen MF. J Viral Hepat. 2011 Jul;18(7):e200-5. doi: 10.1111/j.1365-2893.2010.01428.x. Epub 2011 Jan 7.


  548. Adefovir serum levels do not differ between responders and nonresponders
    Deterding K, Naesens L, Buti M, Janssen H, Kirschner J, Guerrero A, Reijnders J, Neyts J, Zoulim F, Wedemeyer H. J Viral Hepat. 2011 Jul;18(7):e175-8. doi: 10.1111/j.1365-2893.2010.01404.x. Epub 2011 Jan 7.


  549. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection
    Seto WK, Yuen MF, Fung J, Lai CL. Hepatol Int. 2011 Jun 19. [Epub ahead of print]


  550. These were linked to the NSW Department of Health (NSW Health)-identified cases to assess the effectiveness of accessing laboratory data. The laboratories accounted for approximately half of all new HCV notifications in 2007. Of the 2,206 newly diagnosed cases, 21 (1.0%) were newly acquired, 18 of which had not been identified under the current surveillance system, increasing the total number of newly acquired cases to 83 from 65. This increased the yield by 28% and increased the proportion of newly acquired cases from 65/4,192 (1.6%) to 83/4,196 (2.0%). Laboratory-identified cases were significantly more likely than NSW Health-identified cases to be aged 30 years or over. Combined with current reporting mechanisms, laboratory data on previous HCV test results have the potential to increase the number of newly acquired cases identified through the New South Wales surveillance system and to enhance the identification of cases among those aged 30 years or more.
    Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ge YS. Int J Cancer. 2011 Sep 1;129(5):1254-64. doi: 10.1002/ijc.25767. Epub 2011 Jan 6.


  551. Alcohol Consumption Is Inversely Correlated With Insulin Resistance, Independent of Metabolic Syndrome Factors and Fatty Liver Diseases
    Gunji T, Matsuhashi N, Sato H, Iijima K, Fujibayashi K, Okumura M, Sasabe N, Urabe A. J Clin Gastroenterol. 2011 Jun 20. [Epub ahead of print]


  552. Managing patients with hepatitis B-related or hepatitis C-related decompensated cirrhosis
    Fink SA, Jacobson IM. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):285-95.


  553. Should chronic hepatitis B mothers breastfeed? A meta analysis
    Zheng Y, Lu Y, Ye Q, Xia Y, Zhou Y, Yao Q, Wei S. BMC Public Health. 2011 Jun 27;11(1):502. [Epub ahead of print]


  554. Hepatitis B surface antigen monitoring and management of chronic hepatitis B
    Sonneveld MJ, Zoutendijk R, Janssen HL. J Viral Hepat. 2011 Jul;18(7):449-57. doi: 10.1111/j.1365-2893.2011.01465.x. Epub 2011 May 23.


  555. Alcohol Consumption Is Inversely Correlated With Insulin Resistance, Independent of Metabolic Syndrome Factors and Fatty Liver Diseases.
    Gunji T, Matsuhashi N, Sato H, Iijima K, Fujibayashi K, Okumura M, Sasabe N, Urabe A.J Clin Gastroenterol. 2011 Jun 20. [Epub ahead of print]


  556. A Proinflammatory Role For Interleukin-22 In The Immune Response To Hepatitis B Virus
    Zhang Y, Cobleigh MA, Lian JQ, Huang CX, Booth CJ, Bai XF, Robek MD. Gastroenterology. 2011 Jun 24. [Epub ahead of print]


  557. Hepatitis B surface antigen Quantification: Why and How to use it in 2011 - A Core Group Report
    Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao JH, Jia JD, Wedemeyer H, Locarnini S, Janssen HL, Marcellin P; for the Good Practice in using sAg in Chronic Hepatitis B Study Group (GPs-CHB Study Group). J Hepatol. 2011 Jun 27. [Epub ahead of print]


  558. Correlation between maternal hepatitis B surface antigen carrier status with social, medical and family factors in an endemic area: have we overlooked something?
    Chan OK, Lao TT, Suen SS, Lau TK, Leung TY. Infection. 2011 Jun 29. [Epub ahead of print]


  559. Predictive Effect of Serial Serum Alanine Aminotransferase Levels on Spontaneous HBeAg Seroconversion in Chronic Genotypes B and C HBV infected Children
    Wu JF, Su YR, Chen CH, Chen HL, Ni YH, Hsu HY, Wang JL, Chang MH. J Pediatr Gastroenterol Nutr. 2011 Jun 28. [Epub ahead of print]


  560. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy
    Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS. Ann Rheum Dis. 2011 Jun 29. [Epub ahead of print]


  561. Knowledge of Hepatitis B Risk Factors and Prevention Practices among Individuals Chronically Infected with Hepatitis B in San Francisco, California
    Nishimura A, Shiono P, Stier D, Shallow S, Sanchez M, Huang S. J Community Health. 2011 Jun 30. [Epub ahead of print]


  562. Tenofovir nephrotoxicity: 2011 update
    Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Niño MD, Izquierdo MC, Poveda J, Sainz-Prestel V, Ortiz-Martin N, Parra-Rodriguez A, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A. AIDS Res Treat. 2011;2011:354908. Epub 2011 Jun 7.


  563. Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the united states population
    Younossi ZM, Stepanova M. Hepatology. 2011 Jul 2. doi: 10.1002/hep.24510. [Epub ahead of print]


  564. Ethical issues in preventing mother-to-child transmission of hepatitis B by immunisation
    Isaacs D, Kilham HA, Alexander S, Wood N, Buckmaster A, Royle J. Vaccine. 2011 Jun 29. [Epub ahead of print]


  565. Treatment of special populations with chronic hepatitis B infection
    Rapti IN, Hadziyannis SJ. Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):323-39.


  566. Combination Therapy for Chronic Hepatitis B: Current Indications
    Paul N, Han SH. Curr Hepat Rep. 2011 Jun;10(2):98-105. Epub 2011 Feb 19.


  567. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials
    Li WC, Wang MR, Kong LB, Ren WG, Zhang YG, Nan YM. BMC Infect Dis. 2011 Jun 9;11(1):165. [Epub ahead of print]


  568. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy
    Liang Y, Jiang J, Su M, Liu Z, Guo W, Huang X, Xie R, Ge S, Hu J, Jiang Z, Zhu M, Wong VW, Chan HL. Aliment Pharmacol Ther. 2011 Jun 14. doi: 10.1111/j.1365-2036.2011.04738.x. [Epub ahead of print]


  569. Hepatitis B virus infection and pregnancy
    Pol S, Corouge M, Fontaine H. Clin Res Hepatol Gastroenterol. 2011 Jun 7. [Epub ahead of print]


  570. Adverse effects of hepatitis B virus on sperm motility and fertilization ability during IVF
    Oger P, Yazbeck C, Gervais A, Dorphin B, Gout C, Jacquesson L, Ayel JP, Kahn V, Rougier N. Reprod Biomed Online. 2011 May 12. [Epub ahead of print]


  571. Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen Seroconverters
    Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, Chen DS, Kao JH. Gastroenterology. 2011 Apr 28. [Epub ahead of print]


  572. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B
    Poynard T, Ngo Y, Munteanu M, Thabut D, Ratziu V. Curr Hepat Rep. 2011 Jun;10(2):87-97. Epub 2011 Mar 1.


  573. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management
    Liu CJ, Chen PJ, Chen DS, Kao JH. Hepatol Int. 2011 Jun 14. [Epub ahead of print]


  574. Drug safety evaluation of adefovir in HBV infection
    Viganò M, Lampertico P, Colombo M. Expert Opin Drug Saf. 2011 Jun 15. [Epub ahead of print]


  575. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: Virological breakthrough is also dependent on adherence to medication
    Kamezaki H, Kanda T, Wu S, Nakamoto S, Arai M, Maruyama H, Fujiwara K, Imazeki F, Yokosuka O. Scand J Gastroenterol. 2011 May 30. [Epub ahead of print]


  576. Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy
    Ohishi W, Chayama K. Clin Exp Nephrol. 2011 Jun 1. [Epub ahead of print]


  577. Chronic hepatitis B, non-Hodgkin's lymphoma, and effect of prophylactic antiviral therapy
    Kim YM, Jeong SH, Kim JW, Lee SH, Hwang JH, Park YS, Kim N, Lee JS, Kim HY, Lee DH. J Clin Virol. 2011 May 29. [Epub ahead of print]


  578. Chronic Liver Disease in the Hispanic Population of the United States
    Carrion AF, Ghanta R, Carrasquillo O, Martin P. Clin Gastroenterol Hepatol. 2011 May 12. [Epub ahead of print]


  579. The Cost-effectiveness of Screening for Chronic Hepatitis B Infection in the United States
    Eckman MH, Kaiser TE, Sherman KE. Clin Infect Dis. 2011 May 2. [Epub ahead of print]


  580. Dynamic changes of cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, and natural killer T (NKT) cells in patients with acute hepatitis B infection
    Li J, Han Y, Jin K, Wan Y, Wang S, Liu B, Liu Y, Lu S, Huang Z. Virol J. 2011 May 2;8(1):199. [Epub ahead of print]


  581. Hepatitis B virus and renal transplantation
    Kalia H, Fabrizi F, Martin P. Transplant Rev (Orlando). 2011 Apr 27. [Epub ahead of print]


  582. Hepatitis B virus-related hepatocellular carcinoma: primary, secondary, and tertiary prevention
    Giacomin A, Cazzagon N, Sergio A, Vanin V, Farinati F. Eur J Cancer Prev. 2011 May 2. [Epub ahead of print]


  583. Antiretroviral use during pregnancy for treatment or prophylaxis
    Sturt AS, Read JS. Expert Opin Pharmacother. 2011 May 3. [Epub ahead of print]


  584. Breastfeeding of Newborns by Mothers Carrying Hepatitis B Virus: A Meta-analysis and Systematic Review
    Shi Z, Yang Y, Wang H, Ma L, Schreiber A, Li X, Sun W, Zhao X, Yang X, Zhang L, Lu W, Teng J, An Y. Arch Pediatr Adolesc Med. 2011 May 2. [Epub ahead of print]


  585. Efficacy and safety of lamivudine treatment in late pregnancy with high HBV DNA: a perspective for mother and infants
    Köse S, Türken M, Devrim I, Taner C. J Infect Dev Ctries. 2011 Apr 26;5(4):303-6.


  586. The epidemiological pattern of chronic liver diseases in a community undergoing voluntary screening for hepatitis B and C
    Zani C, Pasquale L, Bressanelli M, Puoti M, Paris B, Coccaglio R, Lascioli I, Pieriacci G, Donato F. Dig Liver Dis. 2011 Apr 28. [Epub ahead of print]


  587. Hepatitis B virus infection from an evolutionary point of view: How viral, host, and environmental factors shape genotypes and subgenotypes
    Araujo NM, Waizbort R, Kay A. Infect Genet Evol. 2011 Apr 22. [Epub ahead of print]


  588. Efficacy of an accelerated hepatitis B vaccination program during pregnancy
    Sheffield JS, Hickman A, Tang J, Moss K, Kourosh A, Crawford NM, Wendel GD Jr. Obstet Gynecol. 2011 May;117(5):1130-5.


  589. Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues?
    Campos-Varela I, Castells L, Buti M, Vargas V, Bilbao I, Rodríguez-Frías F, Jardí R, Charco R, Guardia J, Esteban R. Ann Hepatol. 2011 Apr 1;10(2):180-7.


  590. The clinical utility of HBsAg quantitation in chronic hepatitis B patients: A review
    Liaw YF. Hepatology. 2011 Apr 18. doi: 10.1002/hep.24364. [Epub ahead of print]


  591. Emergence of hepatitis B virus S gene mutants in patients experiencing HBsAg seroconversion after peginterferon therapy
    Hsu CW, Yeh CT. Hepatology. 2011 Apr 18. doi: 10.1002/hep.24363. [Epub ahead of print]


  592. Hepatitis B vaccination strategy in vaccine low and non-responders: A matter of quantity of quality?
    Roukens AH, Visser LG. Hum Vaccin. 2011 Jun 1;7(6). [Epub ahead of print]


  593. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score
    Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, Ahn SH, Chen CJ, Wong VW, Seto WK; for the REACH-B Working Group. Lancet Oncol. 2011 Apr 14. [Epub ahead of print]


  594. Chronic HBV with pregnancy: Reactivation flare causing fulminant hepatic failure
    Singhal A, Kanagala R, Jalil S, Wright HI, Kohli V. Ann Hepatol. 2011 Apr 1;10(2):233-6.


  595. Seroprevalence of hepatitis B infection during pregnancy and risk of perinatal transmission
    Dwivedi M, Misra SP, Misra V, Pandey A, Pant S, Singh R, Verma M. Indian J Gastroenterol. 2011 Apr 16. [Epub ahead of print]


  596. The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: A systematic review and meta-analysis
    Zhou Yi ZY, Jie YW, Nan Z. Ann Hepatol. 2011 Apr 1;10(2):165-73.


  597. An Argument for the Universal Prophylaxis of Hepatitis B Infection in Patients Receiving Rituximab: A 7-Year Institutional Experience of Hepatitis Screening
    Leung C, Tsoi E, Burns G, Sievert W. Oncologist. 2011 Apr 4. [Epub ahead of print]


  598. HBV life cycle and novel drug targets
    Grimm D, Thimme R, Blum HE.AbstractHepatol Int. 2011 Mar 8. [Epub ahead of print]


  599. Chronic hepatitis B in pregnancy: unique challenges and opportunities
    Yogeswaran K, Fung SK. Korean J Hepatol. 2011 Mar;17(1):1-8. doi: 10.3350/kjhep.2011.17.1.1.


  600. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial
    Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, Rey D, Colin de Verdière N, Slama L, Martin K, Lortholary O, Carrat F; ANRS HB03 VIHVAC-B Trial. JAMA. 2011 Apr 13;305(14):1432-40.


  601. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance
    Perrillo RP, Hann HW, Schiff E, Mutimer D, Willems B, Leung N, Lee WM, Dixon S, Woessner M, Brosgart CL, Condreay LD, Gardner SD. Hepatol Int. 2011 Jan 5. [Epub ahead of print]


  602. De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients
    Wang LC, Chen EQ, Cao J, Liu L, Zheng L, Li DJ, Xu L, Lei XZ, Liu C, Tang H. Hepatol Int. 2011 Jan 19. [Epub ahead of print]


  603. The influence of hepatitis B and C virus infections on patient and allograft outcomes in kidney transplantation
    Uyar M, Sahin S, Dheir H, Gurkan A.Transplant Proc. 2011 Apr;43(3):850-2.


  604. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma
    Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong CN, Wong J, Lee KF, Lai PB, Chan HL. Aliment Pharmacol Ther. 2011 May;33(10):1104-12. doi: 10.1111/j.1365-2036.2011.04634.x. Epub 2011 Mar 24.


  605. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized open-label study
    Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS Jr, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Hepatology. 2011 Apr 18. doi: 10.1002/hep.24361. [Epub ahead of print]


  606. Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy
    Lao-Araya M, Puthanakit T, Aurpibul L, Taecharoenkul S, Sirisanthana T, Sirisanthana V. Vaccine. 2011 Apr 4. [Epub ahead of print]


  607. Assessing completeness of perinatal hepatitis B virus infection reporting through comparison of immunization program and surveillance data --- United States
    Centers for Disease Control and Prevention (CDC). . MMWR Morb Mortal Wkly Rep. 2011 Apr 8;60(13):410-3.


  608. Pathogenesis of occult chronic hepatitis B virus infection
    de la Fuente RA, Gutiérrez ML, Garcia-Samaniego J, Fernández-Rodriguez C, Lledó JL, Castellano G. World J Gastroenterol. 2011 Mar 28;17(12):1543-8.


  609. Management of occult hepatitis B virus infection: An update for the clinician
    Lledó JL, Fernández C, Gutiérrez ML, Ocaña S. World J Gastroenterol. 2011 Mar 28;17(12):1563-8.


  610. Diagnostic strategy for occult hepatitis B virus infection
    Ocana S, Casas ML, Buhigas I, Lledo JL. World J Gastroenterol. 2011 Mar 28;17(12):1553-7.


  611. Insulin, glucose, and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort
    Chao LT, Wu CF, Sung FY, Lin CL, Liu CJ, Huang CJ, Tsai KS, Yu MW. Carcinogenesis. 2011 Apr 3. [Epub ahead of print]


  612. Increasing burden of liver disease in patients with HIV infection
    Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Lancet. 2011 Apr 2;377(9772):1198-209.


  613. An Argument for the Universal Prophylaxis of Hepatitis B Infection in Patients Receiving Rituximab: A 7-Year Institutional Experience of Hepatitis Screening
    Leung C, Tsoi E, Burns G, Sievert W. Oncologist. 2011 Apr 4. [Epub ahead of print]


  614. Liver transplant and chronic hepatitis B virus infection
    Selcuk H, Karakayali H, Haberal M. Exp Clin Transplant. 2011 Apr;9(2):94-7.


  615. Long-term results of hepatitis B immunoglobulin and lamuvidine for hepatitis B prophylaxis after liver transplantation
    Sevmis S, Aktas S, Zia HH, Atiq A, Akbas E, Selcuk H, Karakayali H, Haberal M. Transplant Proc. 2011 Mar;43(2):598-600.


  616. Posttransplantation prophylaxis with primary high-dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on
    Hwang S, Ahn CS, Song GW, Kim KH, Moon DB, Oh HB, Lim YS, Lee HC, Ha TY, Jung DH, Chung YH, Lee SG. Liver Transpl. 2011 Apr;17(4):456-65. doi: 10.1002/lt.22226.


  617. Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients
    Thibault V, Stitou H, Desire N, Valantin MA, Tubiana R, Katlama C. Antivir Ther. 2011;16(2):199-205.


  618. Initial high dose of lamivudine delays the appearance of viral resistance in chronic hepatitis B patients
    Torre F, Giannini EG, Basso M, Fazio V, Savarino V, Picciotto A. J Gastrointestin Liver Dis. 2011 Mar;20(1):47-50.


  619. Hepatitis B virus (HBV) quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy
    Coffin CS, Mulrooney-Cousins PM, van Marle G, Roberts JP, Michalak TI, Terrault NA. Liver Transpl. 2011 Apr 1. doi: 10.1002/lt.22312. [Epub ahead of print]


  620. Prophylaxis and treatment of hepatitis B infection in the setting of liver transplantation
    D Avola D, Herrero JI. Rev Esp Enferm Dig. 2011 Mar;103(3):142-149.


  621. Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine
    Kobashi H, Miyake Y, Ikeda F, Yasunaka T, Nishino K, Moriya A, Kubota J, Nakamura S, Takaki A, Nouso K, Yamada G, Yamamoto K. Hepatol Res. 2011 Mar 21. doi: 10.1111/j.1872-034X.2011.00785.x. [Epub ahead of print]


  622. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease
    Gisbert JP, Chaparro M, Esteve M. Aliment Pharmacol Ther. 2011 Mar;33(6):619-33.


  623. Liver transplant and chronic hepatitis B virus infection
    Selcuk H, Karakayali H, Haberal M. Exp Clin Transplant. 2011 Apr;9(2):94-7.


  624. Hepatitis B virus (HBV) quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy
    Coffin CS, Mulrooney-Cousins PM, van Marle G, Roberts JP, Michalak TI, Terrault NA. Liver Transpl. 2011 Apr 1. doi: 10.1002/lt.22312. [Epub ahead of print]


  625. Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients
    Thibault V, Stitou H, Desire N, Valantin MA, Tubiana R, Katlama C. Antivir Ther. 2011;16(2):199-205.


  626. Initial high dose of lamivudine delays the appearance of viral resistance in chronic hepatitis B patients
    Torre F, Giannini EG, Basso M, Fazio V, Savarino V, Picciotto A. J Gastrointestin Liver Dis. 2011 Mar;20(1):47-50.


  627. Posttransplantation prophylaxis with primary high-dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on
    Hwang S, Ahn CS, Song GW, Kim KH, Moon DB, Oh HB, Lim YS, Lee HC, Ha TY, Jung DH, Chung YH, Lee SG. Liver Transpl. 2011 Apr;17(4):456-65. doi: 10.1002/lt.22226.


  628. Long-term results of hepatitis B immunoglobulin and lamuvidine for hepatitis B prophylaxis after liver transplantation
    Sevmis S, Aktas S, Zia HH, Atiq A, Akbas E, Selcuk H, Karakayali H, Haberal M. Transplant Proc. 2011 Mar;43(2):598-600.


  629. Liver transplant and chronic hepatitis B virus infection
    Selcuk H, Karakayali H, Haberal M. Exp Clin Transplant. 2011 Apr;9(2):94-7.


  630. Depression in patients with nonalcoholic Fatty liver disease and chronic viral hepatitis B and C
    Weinstein AA, Kallman Price J, Stepanova M, Poms LW, Fang Y, Moon J, Nader F, Younossi ZM. Psychosomatics. 2011 Mar-Apr;52(2):127-32.


  631. Lamivudine treatment is associated with improved survival in fulminant hepatitis B
    Yu JW, Sun LJ, Yan BZ, Kang P, Zhao YH. Liver Int. 2011 Apr;31(4):499-506.


  632. Lamivudine treatment is associated with improved survival in fulminant hepatitis B
    Yu JW, Sun LJ, Yan BZ, Kang P, Zhao YH. Liver Int. 2011 Apr;31(4):499-506.


  633. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in us patients with chronic hepatitis C
    Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR; the HALT-C Trial Group. Hepatology. 2011 Mar 3. [Epub ahead of print]


  634. Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety
    Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Am J Gastroenterol. 2011 Mar 1. [Epub ahead of print]


  635. Recent advances in the management of viral hepatitis
    Holt A. J R Coll Physicians Edinb. 2011 Mar;41(1):59-66.


  636. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus
    Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, Kitrinos K, Svarovskaia ES, Miller MD, Sorbel J, Heathcote J, Marcellin P, Borroto-Esoda K. Hepatology. 2011 Mar;53(3):763-73.


  637. Evaluation of metabolic factors on the prognosis of patients undergoing resection of hepatocellular carcinoma
    Kaibori M, Ishizaki M, Matsui K, Kitade H, Matsui Y, Kwon AH. J Gastroenterol Hepatol. 2011 Mar;26(3):536-43.


  638. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey
    Ioannou GN. Ann Intern Med. 2011 Mar 1;154(5):319-28.


  639. Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: A Systematic review
    Zhao SS, Tang LH, Dai XH, Wang W, Zhou RR, Chen LZ, Fan XG. Virol J. 2011 Mar 9;8(1):111. [Epub ahead of print]


  640. Response to hepatitis B vaccine differs by birthweight among neonates
    Cekmez F, Canpolat FE, Erdinç K, Cetinkaya M, Akin O, Pamuk U, Sarici SU. Vaccine. 2011 Mar 5. [Epub ahead of print]


  641. Nucleic Acid Testing to Detect HBV Infection in Blood Donors
    Susan L. Stramer, Ph.D., Ulrike Wend, Daniel Candotti, Ph.D., Gregory A. Foster, B.A., F. Blaine Hollinger, M.D., Roger Y. Dodd, Ph.D., Jean-Pierre Allain, M.D., and Wolfram Gerlich, M.D.


  642. Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B
    Moucari R, Marcellin P. Liver Int. 2011 Jan;31 Suppl 1:122-8.


  643. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues
    Leung N. Liver Int. 2011 Jan;31 Suppl 1:


  644. Impact of hepatitis B therapy on the long-term outcome of liver disease
    Liaw YF. Liver Int. 2011 Jan;31 Suppl 1:117-21.


  645. Hepatitis B virus resistance to antiviral drugs: where are we going?
    Zoulim F. Liver Int. 2011 Jan;31 Suppl 1:111-6.


  646. Role of occult hepatitis B virus in chronic hepatitis C patients with flare of liver enzymes
    Selim HS, Abou-Donia HA, Taha HA, El Azab GI, Bakry AF. Eur J Intern Med. 2011 Apr;22(2):187-90. Epub 2011 Jan 14.


  647. Hepatitis B vaccination during pregnancy for preventing infant infection
    Sangkomkamhang US, Lumbiganon P, Laopaiboon M. Cochrane Database Syst Rev. 2011 Mar 16;3:CD007879.


  648. Importance of maternal and cord blood viremia in pregnant women with chronic hepatitis B virus infection
    Elefsiniotis IS, Tsoumakas K, Papadakis M, Vlachos G, Saroglou G, Antsaklis A. Eur J Intern Med. 2011 Apr;22(2):182-6. Epub 2011 Jan 7.


  649. Antioxidant supplements for liver diseases
    Bjelakovic G, Gluud LL, Nikolova D, Bjelakovic M, Nagorni A, Gluud C. Cochrane Database Syst Rev. 2011 Mar 16;3:CD007749.


  650. Student vaccination requirements of u.s. Health professional schools: a survey
    Lindley MC, Lorick SA, Spinner JR, Krull AR, Mootrey GT, Ahmed F, Myers R, Bednash GP, Cymet TC, Maeshiro R, Raines CF, Shannon SC, Sondheimer HM, Strikas RA. Ann Intern Med. 2011 Mar 15;154(6):391-400.


  651. A Prospective Study of Hepatitis B Vaccination - A Comparison of Responders versus Nonresponders
    Brown CM, Donlon S, O'Kelly P, Casey AM, Collier C, Conlon PJ, Walshe JJ. Ren Fail. 2011;33(3):276-9.


  652. Prophylaxis against de novo hepatitis B for liver transplantation utilizing hep B core (+) donors: does hepatitis B immunoglobulin provide a survival advantage?
    Brock GN, Mostajabi F, Ferguson N, Carrubba CJ, Eng M, Buell JF, Marvin MR. Transpl Int. 2011 Mar 15. doi: 10.1111/j.1432-2277.2011.01236.x. [Epub ahead of print]


  653. Trends in all cause and liver-related hospitalizations in people with hepatitis B or C: a population-based linkage study
    Gidding HF, Dore GJ, Amin J, Law MG. BMC Public Health. 2011 Jan 24;11(1):52. [Epub ahead of print]


  654. Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection
    Kramer JR, Hachem CY, Kanwal F, Mei M, El-Serag HB. Hepatology. 2011 Jan;53(1):42-52.


  655. Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta
    Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Cakalo?lu Y, De?ertekin H, Gürel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP; the HIDIT Study Group. N Engl J Med. 2011 Jan 27;364(4):322-331.


  656. Posttransplantation Hepatitis B Prophylaxis with Combination Oral Nucleoside and Nucleotide Analog Therapy
    Saab S, Desai S, Tsaoi D, Durazo F, Han S, McClune A, Holt C, Farmer D, Goldstein L, Busuttil RW. Am J Transplant. 2011 Feb 7. [Epub ahead of print]


  657. Usefulness of Multiple Biomarkers for the Prediction of Significant Fibrosis in Chronic Hepatitis B
    Park SH, Kim CH, Kim DJ, Suk KT, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Kim YB. J Clin Gastroenterol. 2011 Feb 4. [Epub ahead of print]


  658. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period
    Hamabe A, Uto H, Imamura Y, Kusano K, Mawatari S, Kumagai K, Kure T, Tamai T, Moriuchi A, Sakiyama T, Oketani M, Ido A, Tsubouchi H. J Gastroenterol. 2011 Feb 8. [Epub ahead of print]


  659. Quantitative DNA analysis of very low-level hepatitis B viremic patients reporting to the gastroenterology clinic
    Bamaga MS, Sobahy TM, Attar AS. Saudi Med J. 2011 Feb;32(2):135-40.


  660. Influenza, hepatitis B, and tetanus vaccination coverage among health care personnel in the United States
    Lu PJ, Euler GL. Am J Infect Control. 2011 Jan 31. [Epub ahead of print]


  661. A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective
    Post SE, Sodhi NK, Peng CH, Wan K, Pollack HJ. Health Aff (Millwood). 2011 Feb;30(2):340-8.


  662. Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients
    Fabrizi F, Dixit V, Martin P, Messa P. Aliment Pharmacol Ther. 2011 Feb 1. [Epub ahead of print]


  663. Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents
    Cheng PN, Liu WC, Tsai HW, Wu IC, Chang TT, Young KC. J Med Virol. 2011 Apr;83(4):602-7.


  664. Medication Nonadherence with Long-Term Management of Patients with Hepatitis B e antigen-Negative Chronic Hepatitis B
    Ha NB, Ha NB, Garcia RT, Trinh HN, Chaung KT, Nguyen HA, Nguyen KK, Levitt BS, Nguyen MH. Dig Dis Sci. 2011 Feb 17. [Epub ahead of print]


  665. Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study
    Feuchtenberger M, Kleinert S, Schwab S, Roll P, Scharbatke EC, Ostermeier E, Voll RE, Schäfer A, Tony HP. Rheumatol Int. 2011 Feb 15. [Epub ahead of print]


  666. Combined use of wild-type HBV precore and high serum iron marker as a potential tool for the prediction of cirrhosis in chronic Hepatitis B infection
    Chook JB, Ngeow YF, Yap SF, Tan TC, Mohamed R. J Med Virol. 2011 Apr;83(4):594-601.


  667. Natural History of Chronic Hepatitis B REVEALed
    Chen CJ, Yang HI. J Gastroenterol Hepatol. 2011 Feb 16. [Epub ahead of print]


  668. Tenofovir Therapy in Hepatitis B Virus-Positive Solid-Organ Transplant Recipients
    Daudé M, Rostaing L, Sauné K, Lavayssière L, Basse G, Esposito L, Guitard J, Izopet J, Alric L, Kamar N. Transplantation. 2011 Feb 15. [Epub ahead of print]


  669. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir/emtricitabine) experienced patients
    Ratcliffe L, Beadsworth MB, Pennell A, Phillips M, Vilar FJ. AIDS. 2011 Feb 22. [Epub ahead of print]


  670. A simple method to measure antibody affinity against the hepatitis B surface antigen using a routine quantitative system
    Liu H, Han Y, Wang B. J Virol Methods. 2011 Feb 21. [Epub ahead of print]


  671. Notes from the Field: Deaths from Acute Hepatitis B Virus Infection Associated with Assisted Blood Glucose Monitoring in an Assisted-Living Facility --- North Carolina, August--October 2010
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011 Feb 18;60(6):182.


  672. Potential transmission of viral hepatitis through use of stored blood vessels as conduits in organ transplantation --- pennsylvania, 2009
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011 Feb 18;60(6):172-4.


  673. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients
    Chen CH, Lee CM, Hung CH, Wang JH, Hu TH, Changchien CS, Lu SN. J Gastroenterol Hepatol. 2011 Mar;26(3):461-8.


  674. Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naive Asian patients with chronic hepatitis B: a meta-analysis
    Zhao P, Liu WW, Zhao J, Guan Q. Virol J. 2011 Feb 22;8(1):75. [Epub ahead of print]


  675. Evaluation of Current Treatment Recommendations for Chronic Hepatitis B: A 2011 Update
    Tong MJ, Hsu L, Chang PW, Blatt LM. J Gastroenterol Hepatol. 2011 Jan 10. [Epub ahead of print]


  676. A Model to Determine 3-Month Mortality Risk in Patients With Acute-on-Chronic Hepatitis B Liver Failure
    Zheng MH, Shi KQ, Fan YC, Li H, Ye C, Chen QQ, Chen YP. Clin Gastroenterol Hepatol. 2010 Dec 30. [Epub ahead of print]


  677. Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century.
    Dwyre DM, Fernando LP, Holland PV. Vox Sang. 2011 Jan;100(1):92-8.


  678. HIV and Hepatitis B and C Incidence Rates in US Correctional Populations and High Risk Groups: A systematic review and meta-analysis
    Gough E, Kempf MC, Graham L, Manzanero M, Hook EW 3rd, Bartolucci A, Chamot E. BMC Public Health. 2010 Dec 21;10(1):777.


  679. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B
    Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok AS. J Hepatol. 2011 Jan;54(1):12-8.


  680. Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B
    Heathcote EJ, Marcellin P, Buti M et al.Gastroenterol 2011;140 (1):132-143.


  681. Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?
    Rijckborst V, Sonneveld MJ, Janssen HL. Aliment Pharmacol Ther. 2010 Dec 29. [Epub ahead of print]


  682. Natural history of chronic HBV infection: special emphasis on the prognostic implications of the inactive carrier state versus chronic hepatitis
    Villa E, Fattovich G, Mauro A, Pasino M. Dig Liver Dis. 2011 Jan;43S1:S8-S14.


  683. HBV therapy: Guidelines and open issues
    Alberti A, Caporaso N. Dig Liver Dis. 2011 Jan;43S1:S57-S63


  684. Development of a protocol for the quantitative determination of HBeAg using the Elecsys(®) HBeAg immunoassay
    Wursthorn K, Zacher BJ, Jaroszewicz J, Dernedde M, Manns M, Wedemeyer H. J Viral Hepat. 2010 Dec 30. [Epub ahead of print]


  685. Antiviral drugs for HBV liver disease
    Vigano M, Lampertico P. Expert Opin Biol Ther. 2011 Jan 5. [Epub ahead of print]


  686. Systematic Review of the Literature on Comparative Effectiveness of Antiviral Treatments for Chronic Hepatitis B Infection
    Shamliyan TA, Johnson JR, Macdonald R, Shaukat A, Yuan JM, Kane RL, Wilt TJ. J Gen Intern Med. 2011 Jan 4. [Epub ahead of print]


  687. Application of the HALF index obviates the need for liver biopsy in half of all patients with chronic hepatitis B
    Lee HJ, Seo YS, Kim DJ, Kang HS, An H, Kim JH, Cheong JY, Yim HJ, Yeon JE, Lee HS, Byun KS, Cho SW, Kim DJ, Um SH, Kim CD, Ryu HS. J Gastroenterol Hepatol. 2010 Dec 28. [Epub ahead of print]


  688. Antiviral therapy for hepatitis B in special populations
    Zhang FK, Liu DG, Jia JD. Antivir Ther. 2010;15(8):1067-75.


  689. Caring for pregnant women and newborns with hepatitis B or C
    Lam NC, Gotsch PB, Langan RC. Am Fam Physician. 2010 Nov 15;82(10):1225-9.


  690. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports
    Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, Dai MS, Chiu BC, Fintel B, Cheng Y, Chuang SS, Lee MY, Chen TY, Lin SF, Kuo CY. Ann Oncol. 2010 Nov 29. [Epub ahead of print]


  691. Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection
    Watanabe M, Shibuya A, Tsunoda Y, Danbara M, Ishii R, Ohsaka M, Takada J, Tanaka Y, Okuwaki Y, Minamino T, Hidaka H, Nakazawa T, Horie R, Higashihara M, Koizumi W. Liver Int. 2010 Dec 7. [Epub ahead of print]


  692. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B
    Su TH, Hsu CS, Chen CL, Liu CH, Huang YW, Tseng TC, Liu CJ, Chen PJ, Lai MY, Chen DS, Kao JH. Antivir Ther. 2010;15(8):1133-9.


  693. San Francisco Hep B Free: A Grassroots Community Coalition to Prevent Hepatitis B and Liver Cancer
    Bailey MB, Shiau R, Zola J, Fernyak SE, Fang T, So SK, Chang ET. J Community Health. 2010 Dec 2. [Epub ahead of print]


  694. Host factors may influence response to antiviral therapy in chronic hepatitis B virus infections
    Schildgen O. Med Hypotheses. 2010 Nov 27. [Epub ahead of print]


  695. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B
    Schiff ER, Lee SS, Chao YC, Yoon SK, Bessone F, Wu SS, Kryczka W, Lurie Y, Gadano A, Kitis G, Beebe S, Xu D, Tang H, Iloeje U. Clin Gastroenterol Hepatol. 2010 Dec 7. [Epub ahead of print]


  696. Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience
    Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM. Liver Int. 2010 Dec 8. doi: 10.1111/j.1478-3231.2010.02416.x. [Epub ahead of print]


  697. Hepatitis B e-antigen Persistency is Associated with the Properties of HBV-Specific CD8 T Cells in CHB Patients
    Peng G, Luo B, Li J, Zhao D, Wu W, Chen F, Chen Z. J Clin Immunol. 2010 Dec 1. [Epub ahead of print]


  698. Is chronic hepatitis B being undertreated in the United States?
    Cohen C, Holmberg SD, McMahon BJ, Block JM, Brosgart CL, Gish RG, London WT, Block TM. J Viral Hepat. 2010 Dec 8.. [Epub ahead of print]


  699. Obstetrician-gynecologists and perinatal infections: a review of studies of the collaborative ambulatory research network (2005-2009)
    Leddy MA, Gonik B, Schulkin J. Infect Dis Obstet Gynecol. 2010;2010:583950. Epub 2010 Nov 11.


  700. Infection with hepatitis B and C viruses and risk of lymphoid malignancies in the European Prospective Investigation into Cancer and Nutrition (EPIC)
    Franceschi S, Lise M, Trepo C, Berthillon P, Chuang SC, Nieters A, Travis RC, Vermeulen R, Overvad K, Tjonneland AM, Olsen A, Bergmann M, Boeing H, Kaaks R, Becker N, Trichopoulou A, Lagiou P, Bamia C, Palli D, Sieri SA, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Peeters PH, Rodriguez L, Lujan Barroso L, Dorronsoro M, Sanchez MJ, Navarro C, Barricarte Gurrea A, Regner S, Borgquist S, Melin B, Hallmans G, Khaw KT, Wareham NJ, Rinaldi S, Hainaut P, Riboli E, Vineis P. Cancer Epidemiol Biomarkers Prev. 2010 Nov 23. [Epub ahead of print


  701. The efficacy of social role models to increase motivation to obtain vaccination against hepatitis B among men who have sex with men
    Vet R, de Wit JB, Das E. Health Educ Res. 2010 Nov 24. [Epub ahead of print]


  702. An outbreak of hepatitis B with high mortality in India: association with precore, basal core promoter mutants and improperly sterilized syringes
    Arankalle VA, Gandhi S, Lole KS, Chadha MS, Gupte GM, Lokhande MU. J Viral Hepat. 2010 Nov 26. [Epub ahead of print]


  703. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir
    Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, Hansen BE, Janssen HL. J Hepatol. 2010 Nov 5. [Epub ahead of print]


  704. Acute hepatitis B in Japan: Incidence, clinical practices and health policy
    Sako A, Yasunaga H, Horiguchi H, Hashimoto H, Masaki N, Matsuda S. Hepatol Res. 2010 Nov 25. [Epub ahead of print]


  705. Treatment of chronic hepatitis B: adherence and safety
    Pol S, Sogni P. Gastroenterol Clin Biol. 2010 Sep;34S2:S142-S148.


  706. Chronic hepatitis B: perceptions in asian american communities and diagnosis and management practices among primary care physicians
    Upadhyaya N, Chang R, Davis C, Conti MC, Salinas-Garcia D, Tang H. Postgrad Med. 2010 Sep;122(5):165-75.


  707. The impact of smoking on incident type 2 diabetes in a cohort with hepatitis B but not hepatitis C infection
    Wang CS, Chang TT, Yao WJ, Wang ST, Chou P. Viral Hepat. 2010 Aug 31. [Epub ahead of print]


  708. Hepatitis B Genotype C Correlated with Poor Surgical Outcomes for Hepatocellular Carcinoma
    Liang TJ, Mok KT, Liu SI, Huang SF, Chou NH, Tsai CC, Chen IS, Yeh MH, Chen YC, Wang BW. J Am Coll Surg. 2010 Sep 17. [Epub ahead of print]


  709. Successful hepatitis B immunization in non- and low responding health care workers
    Heininger U, Gambon M, Gruber V, Margelli D. Hum Vaccin. 2010 Sep 19;6(9). [Epub ahead of print]


  710. Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients
    Reuter S, Oette M, Wilhelm FC, Beggel B, Kaiser R, Balduin M, Schweitzer F, Verheyen J, Adams O, Lengauer T, Fätkenheuer G, Pfister H, Häussinger D. Med Microbiol Immunol. 2010 Sep 19. [Epub ahead of print]


  711. National, state, and local area vaccination coverage among children aged 19-35 months --- United States, 2009
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2010 Sep 17;59(36):1171-7.


  712. Endpoints of hepatitis B treatment
    Chotiyaputta W, Lok AS. J Viral Hepat. 2010 Oct;17(10):675-84.


  713. A Proposed, Evidence-based Approach to the Treatment of Chronic Hepatitis B
    Han SH, Durazo FA, Saab S, Tong MJ. J Clin Gastroenterol. 2010 Sep 17. [Epub ahead of print]


  714. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study)
    Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, Bedossa P; for the FIBROSTIC study group. J Hepatol. 2010 Aug 14. [Epub ahead of print]


  715. Asymptomatic chronic hepatitis B virus infection does not increase the risk of diabetes mellitus: a ten-year observation.
    Huang ZS, Huang TS, Wu TH, Chen MF, Hsu CS, Kao JH. J Gastroenterol Hepatol. 2010 Aug;25(8):1420-5.


  716. Safety evaluation of telbivudine
    But DY, Yuen MF, Fung J, Lai CL. Expert Opin Drug Saf. 2010 Jul 27. [Epub ahead of print]


  717. Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): Molecular mechanisms and novel paradigms
    Brechot C, Kremsdorf D, Soussan P, Pineau P, Dejean A, Paterlini-Brechot P, Tiollais P. Pathol Biol (Paris). 2010 Jul 26. [Epub ahead of print]


  718. Prevalence of Hepatitis B Surface Antigen in US-Born and Foreign-Born Asian/Pacific Islander College Students
    Quang YN, Vu J, Yuk J, Li CS, Chen M, Bowlus CL. J Am Coll Health. 2010 Jul-Aug;59(1):37-41.


  719. Implementing a birth dose of hepatitis B vaccine for home deliveries in Africa-Too soon?
    Kramvis A, Clements CJ. Vaccine. 2010 Jul 27. [Epub ahead of print]


  720. Hepatitis B virus genotyping: current methods and clinical implications
    Guirgis BS, Abbas RO, Azzazy HM. Int J Infect Dis. 2010 Jul 29. [Epub ahead of print]


  721. Resistance mutation patterns of hepatitis B virus in patients with suboptimal response to adefovir dipivoxil therapy after lamivudine resistance
    Wu ZP, Hang T, Gao YT, Li Y, Liu T, Jing L, Liu L, DU Z. Zhonghua Gan Zang Bing Za Zhi. 2010 Jul;18(7):498-501. doi: 10.3760/cma.j.issn.1007-3418.2010.07.007.


  722. Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies
    Yagci M, Ozkurt ZN, Yegin ZA, Aki Z, Sucak GT, Haznedar R. Hematology. 2010 Aug;15(4):240-244.


  723. Celiac Disease as a Cause of Abnormal Transaminases in Chronic Hepatitis B Infection
    Clark LE, Herrera JL. PRACTICAL GASTROENTEROLOGY • DECEMBER 2003;27:50-51.


  724. Chronic Hepatitis B: Who and How to Treat
    Landreneau SW, Herrera JL. PRACTICAL GASTROENTEROLOGY • NOVEMBER 2007;31:25-40.


  725. Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant chronic hepatitis B
    Jung YK, Yeon JE, Han WS, Kim JH, Kim JH, Park JJ, Kim JS, Bak YT, Yoo W, Hong SP, Kim SO, Kwon SY, Byun KS, Lee CH. Gut Liver. 2010 Jun;4(2):212-8. Epub 2010 Jun 16.


  726. Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: a novel role of alpha-fetoprotein
    Lee IC, Huang YH, Chan CC, Huo TI, Chu CJ, Lai CR, Lee PC, Su CW, Hung HH, Wu JC, Lin HC, Lee SD. Liver Int. 2010 Jun 15. [Epub ahead of print]


  727. Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis
    Wu B, Li T, Chen H, Shen J. Value Health. 2010 Apr 30. [Epub ahead of print]


  728. Does chemotherapy prevent HBV-related hepatocellular carcinoma? Cons
    Colombo M. Dig Liver Dis. 2010 Jul;42 Suppl 3:S298-301.


  729. On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective
    Chien RN. J Gastroenterol Hepatol. 2010 May;25(5):852-7.


  730. Overlap/switch to adefovir monotherapy for lamivudine-resistant patients who responded to combination therapy: a pilot controlled study
    Aizawa M, Tsubota A, Fujise K, Sato K, Baba M, Takamatsu M, Namiki Y, Ohkusa T, Tajiri H. Intern Med. 2010;49(12):1067-72. Epub 2010 Jun 15.


  731. PNA Array for Detection of Point Mutations in Hepatitis B Virus Associated with Antiviral Resistance
    Jang H, Kim J, Choi JJ, Son Y, Park H. J Clin Microbiol. 2010 Jun 23. [Epub ahead of print]


  732. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis
    Shi Z, Yang Y, Ma L, Li X, Schreiber A. Obstet Gynecol. 2010 Jul;116(1):147-59.


  733. Long-Term Outcome of Renal Transplant Recipients With Chronic Hepatitis B Infection-Impact of Antiviral Treatments
    Yap DY, Tang CS, Yung S, Choy BY, Yuen MF, Chan TM. Transplantation. 2010 Jun 17. [Epub ahead of print]


  734. Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients
    Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Kumada H. J Gastroenterol Hepatol. 2010 May;25(5):892-8.


  735. Chronic Viral Infections and Invasive Procedures: Risk of Vertical Transmission and Current Recommendations
    López M, Coll O. Fetal Diagn Ther. 2010 Jun 19. [Epub ahead of print]
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare
providers only. Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.